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Glioblastoma multiforme (GBM) is the most common and lethal type of brain tumor in adults. 
There are some evidences that it is maintained by a population of cells, namely cancer stem cells, 
able to self-renew and propagate the tumor. Despite recent advances in surgical and therapeutic 
treatment, no tangible improvements have been made to prolong the patients’ survival. 
The role of the cell surface CD133 as a cancer stem cell marker in brain tumors has been widely 
investigated, since it identifies cells within glioblastomas able to initiate neurosphere growth and 
form heterogeneous tumors when transplanted in immune-compromised mice. However, evidences 
of CD133-negative cells exhibiting similar properties have been reported, making definitive 
conclusions on the correlation between tumor-initiating capabilities of glioma stem cells and 
CD133 expression difficult to drawn. Moreover, the functional role of CD133 in cancer 
stem/progenitor cells is not known.  
We analyzed the efficiency of CD133 in the identification and isolation of glioblastoma stem cells 
and we investigated its functional role, studying the biological effects of CD133 down-regulation in 
GBM-derived neurospheres in vitro and in vivo. 
We observed that CD133 is homogenously expressed in the cytoplasm of the cells composing the 
neurospheres, while its expression on the cell surface is highly variable. Cloning of single CD133-
positive and CD133-negative cells demonstrated that CD133 shuttles dynamically between the 
plasmamembrane and the cell cytoplasm and no hierarchical relation can be established. 
Knockdown of CD133 by lentiviral-mediated short hairpin RNAs (shRNA) reduces the self-
renewal and tumorigenic capacity of the GBM-derived neurosphere cells. 
Taken together, our data suggest that cell surface CD133 is not useful for the isolation of 
glioblastoma stem cells, since a complex regulation of its expression in terms of protein levels and 
cellular localization exists.  However, CD133 may contribute to the maintenance and the 
tumorigenic potential of glioblastoma stem cells. This implies that CD133 could be used as a 





1.1 Brain tumors 
Gliomas are a heterogeneous group of oncological diseases, characterized by complex cellular 
composition and diffuse invasiveness. These tumors diffusely infiltrate the surrounding normal 
tissue and have a strong tendency to progress into a malignant and then fatal outcome.	  
Over the last years our knowledge about brain tumors has increased significantly, especially 
important progresses have been made on glioblastoma, the most aggressive among brain tumors, 
and unfortunately the most common.	  
The demonstration of the existence of cancer stem cells has shed light on some issues such as the 
cell of origin of these tumors and the characteristics of cells resistant to conventional therapies. The 
development of new animal models and large-scale genomic analysis allowed the identification of 
mutations that drive tumor development. International organizations comprising several institutes 
around the world, such as The Cancer Genome Atlas (TCGA), were created with the mission of 
understanding ‘the molecular basis of cancer through the application of genome analysis 
technologies’ (TCGA, 2008) and especially selected glioblastoma as the first cancer type for study, 
based on its uniformly poor prognosis and limited treatment options. TCGA permitted the 
collection of a great amount of data relating to brain tumors and the creation of web-tools freely 
accessible by the entire scientific community. 
With these advances in our understanding about the biology of glioblastoma, improvements have 
come in therapy. Sadly, despite some advances in treatment, the overall survival of GBM patients 
cases is still not substantially different compared to the last decade.	  	  
 
1.1.1 Epidemiology of gliomas 
Gliomas are the most common primary tumors of the central nervous system. Every year 
approximately five of hundred thousand individuals are diagnosed with glioma; the 60-70% of 
them is represented by the glioblastoma multiforme. Individuals of all ages can be affected but they 
are most common among elderly people. The peak of onset of glioblastomas is around 50 - 55 
years, with men slightly more prone to these neoplasms. Furthermore, the incidence is 2 - 3 times 
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higher in white than in black people (Wen & Kesari, 2008). Prognosis is poor and the median 
survival is 14.6 months (Stupp et al, 2007); only few patients survive for three or more years. Main 
risk factors are high dose radiation, hereditary syndromes and increasing age. Only 5% of patients 
have a family history of gliomas: in most cases they are affected by rare genetic syndromes, such as 
neurofibromatosis type 1 and 2, the Li-Fraumeni syndrome and Turcot’s syndrome. However, the 
genetic bases of malignant gliomas have not been identified yet.   
 
1.1.2 Morphological classification of gliomas 
Gliomas are classified according to the World Health Organization (WHO) guidelines (Louis et al, 
2007). This classification system is based mainly on histopathology, according to morphological 
similarities between tumor cells and normal glial cells, cytoarchitecture and immunohistological 
marker profile. The WHO divides the diffuse gliomas into three main categories: astrocytomas 
(related to astrocytes), oligodendrogliomas (related to oligodendrocytes) and oligoastrocytomas 
(related to a mixture of these two cell types), and a grading system was created as a scale of 
malignancy. Four grades (I, II, III, and IV) distinguish astrocytomas and two grades (II and III) 
oligodendrogliomas and oligoastrocytomas. Lower grade astrocytomas (grade I-II) are well 
differentiated, have increased cell density and some cellular anomalies or atypias, but in general 
they resemble the non-neoplastic tissue. Tumors of higher grade (grade III tumors) are anaplastic 
with nuclear atypia, increased vessels and cell density and elevated mitotic activity. The grade IV 
astrocytoma, also known as glioblastoma multiforme (GBM), exhibits the additional presence of 
microvascular proliferation, necrosis and diffuse infiltration throughout the brain parenchyma, 
which denote the fully malignant state. The moniker “multiforme” derives from the varied 
morphological features of this tumor, in which heterogeneous cell populations with high degree of 
cellular and nuclear polymorphism and numerous giant cells coexist with area of high cellular 
uniformity. 
Glioblastoma can be separated into two main subtypes on the basis of clinical presentation and 
biological and genetic differences (Furnari et al, 2007; Ohgaki & Kleihues, 2007) (Figure 1). 
Primary glioblastomas occur de novo with no previous lower grade pathology, typically in patients 
older than 50 years of age. On the contrary, secondary glioblastomas are quite rare and are 
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manifested in younger patients as low grade or anaplastic astrocytomas that worsen over a period 
of 5-10 years into glioblastoma. Late-stage mixed gliomas or oligodendrogliomas can also 
resemble glioblastoma (Miller & Perry, 2007). Primary and secondary glioblastomas present 
distinct genetic alterations affecting similar molecular pathway. Primary GBMs are characterized 
by EGFR amplification and mutations, loss of heterozygosity of chromosome 10q, deletions of 
PTEN and p16. Secondary GBMs are more frequently characterized by mutations in p53 tumor 
suppressor gene, over-expression of PDGFR, abnormalities in the p16 and Rb pathways, and loss 
of heterozigosity of chromosome 10q. Despite the genetic differences and their distinct clinical 
course, primary and secondary glioblastomas are morphologically indistinguishable and respond 







Figure 1. Chromosomal and genetic aberrations involved in the genesis of glioblastoma. 
Pathobiologies, survival, genetic and chromosomal alterations involved in the development of primary and 
secondary glioblastomas are shown. Although histologically indistinguishable, these grade IV gliomas occur 
in different age groups and present distinct genetic alterations affecting similar molecular pathways. (OE) 





1.1.3 Genetic abnormalities in gliomas 
Numerous molecular abnormalities are linked to the pathogenesis of different glioma variants. The 
comparative genomic hybridization analyses (CGH) and the large-scale integrated genomic 
analyses (Parsons et al, 2008; TCGA, 2008) have resulted in more comprehensive analyses of the 
molecular aberrations underlying gliomagenesis. The Cancer Genome Atlas (TCGA) has so far 
accumulated expression, copy number alterations and sequencing data from hundreds of 
histologically confirmed glioblastomas and has comprehensively catalogued the genomic 
anomalies associated with GBM. Furthermore, the biological relevance of many of these molecular 
abnormalities to the process of gliomagenesis has been confirmed by mouse modeling studies 
(Huse & Holland, 2009). 
Genetic alterations characteristic of astrocytic glioma lead to aberrant activation of key signaling 
pathways mainly those involved in mitogenic signaling and cell cycle control. 
 
1.1.3.1 Growth factor pathways 
Alterations of the receptor tyrosine kinases (RTKs) and their associated downstream pathways 
occur in a large percentage of diffuse gliomas and appear to be critical to oncogenesis in these 
tumors. Genomic amplification and activating mutations in the EGFR locus occur almost 
exclusively in primary glioblastomas and represent the most prevalent RTK-associated molecular 
abnormality in malignant glioma (~45% of GBM). About half of the tumors with EGFR 
amplification express a constitutively autophosphorylated variant of EGFR, known as EGFRvIII, 
that lacks the extracellular ligand-binding domain (exon 2 through 7) (Frederick et al, 2000; 
Furnari et al, 2007; Pelloski et al, 2007). 
Enhanced PDGF signaling, either through receptor (PDGFR) amplification/mutation or through 
ligand over-expression has been found to be a common feature of low grade gliomas along with a 
significant subset of glioblastomas (Westermark et al, 1995).  Although activating mutations in 
PDGFRA are uncommon (Clarke & Dirks, 2003), frequent co-expression of both receptor and its 
ligand, most commonly PDGFB, indicates the potential for autocrine or paracrine loops boosting 
oncogenic signaling through the PDGF network. 
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Hepatocyte growth factor (HGF) and its RTK MET (also known as HGFR) appear to operate in a 
smaller subset of GBMs (Abounader & Laterra, 2005), as does the RTK ligand IGF2 (Soroceanu et 
al, 2007). 
Common signal transduction pathway activated by growth factors is the MAPK pathway, which is 
involved in proliferation and cell cycle progression, and the PI3K-Akt-mTOR pathway, which is 
involved in the inhibition of apoptosis and cellular proliferation. Further dysregulation of the 
downstream PI3K-AKT-mTOR and Ras-MAPK signaling pathways also exists in the majority of 
malignant gliomas (Furnari et al, 2007). Mutations in the catalytic or regulatory domain of PI3K 
that are hypothesized to lead to its constitutive activation occur in 15% of GBMs. Notably, PTEN 
and NF1, important negative regulators of the PI3K-AKT-mTOR and Ras-MAPK networks, 
respectively, are frequently mutated or deleted in GBM (36% and 18%, respectively), and loss of 
PTEN at the protein level is found in more than 80% (TCGA, 2008). 
 
1.1.3.2 Cell cycle regulators  
p53 and RB functions are inhibited by mutations or copy number alterations in at least 87% and 
78% of GBMs, respectively (TCGA, 2008). Additionally, mutations in the TP53 gene frequently 
characterize low-grade astrocytomas and the secondary glioblastomas into which they evolve 
(Furnari et al, 2007). The Rb tumor suppressor pathway has been shown to be defective in a 
significant number of high-grade gliomas of both astrocytic and oligodendroglial lineage, either by 
inactivating mutations in RB1 itself or by amplification of its negative regulators CDK4 and, less 
frequently, CDK6 (Costello et al, 1997; Henson et al, 1994). Analogously, amplification of the p53 
antagonists MDM2 and MDM4 have also been found in distinct subsets of Tp53‑intact 
glioblastomas, as mutations and/or deletions in the CDKN2A locus that encodes both INK4A and 
ARF, which are crucial positive regulators of RB and p53, respectively. 
 
1.1.3.3 Other genetic alterations 
Integrated genomic analysis has facilitated the identification and characterization of additional 
genes involved in glioma pathogenesis. Missense mutations in IDH1 are found in a significant 
number of glioblastomas that tend to occur mostly in younger patients with more protracted clinical 
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courses (Parsons et al, 2008). These point mutations are restricted exclusively to the R132 residue 
in the active site region of the protein in which they disrupt hydrogen binding with its substrate 
(Parsons et al, 2008; Yan et al, 2009). Interestingly, a separate group of gliomas harbor mutations 
in the IDH1 homologue IDH2 at the analogous residue (R172). Further investigations have shown 
that mutations in IDH1 and IDH2 are present in a high proportions of grade II and III astrocytic and 
oligodendroglial tumors (72–100%) along with secondary glioblastomas (85%), but are largely 
absent in primary glioblastomas (5%) (Hartmann et al, 2009; Yan et al, 2009). Furthermore, across 
all histological types of diffuse glioma, IDH mutations tend to segregate with other low-grade 
glioma-associated genomic abnormalities, such as TP53 mutations and 1p/19q deletion, and are not 
associated with EGFR amplification and chromosome 10 loss, anomalies occurring frequently in 
primary GBM. These findings define an oncologic pathway for low-grade gliomas and the 
malignant tumors into which they evolve, which is distinct from the one used by de novo primary 
GBM. The IDH1 mutation is associated with longer survival (Hartmann et al, 2010) of patients 
with secondary glioblastoma and thus may be a highly valuable prognostic biomarker (von 
Deimling et al, 2011). IDH mutational status has also been linked with DNA methylation profiles 
in diffuse glioma. Recent analysis by TCGA has demonstrated a small subset of GBMs (8.8%), 
which exhibit a G-CIMP characterized by stereotyped hypermethylation of CpG islands in over 
1,500 loci across the genome (Noushmehr et al, 2010). G-CIMP-positive GBMs exhibit increased 
frequency of characteristic copy number alterations (CNAs) in 8q and 10p and are highly enriched 
for IDH mutations. By report, approximately 87% of G-CIMP-positive versus 5% of G-CIMP-
negative tumors was IDH-mutant, combining TCGA data with a validated tumor set. The striking 
correlation between G-CIMP and IDH mutation is common across all diffuse glioma variants, 
especially in lower-grade astrocytomas and oligodendrogliomas. 
  
1.1.4 Molecular classification of gliomas. 
The WHO glioma classification has shown a remarkable prognostic power, however considerable 
variability in clinical outcome among patients within each diagnostic category still exists. This is 
mainly due to the molecular complexity of gliomas and it has created the need of a more accurate 
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classification of gliomas. The identification of prognostically distinct molecular subtypes within 
otherwise morphologically homogeneous gliomas is also crucial. 
Gene expression profiling studies have been used to identify subclasses of gliomas based on 
transcriptional signatures. Earliest studies identified gene expression differences among 
morphologically defined gliomas. Differentially expressed genes were found among GBM and 
lower grade gliomas (Fuller et al, 2002; Li et al, 2009; Nutt et al, 2003; Rickman et al, 2001; Shai 
et al, 2003; Shirahata et al, 2007) primary and secondary GBMs (Godard et al, 2003; Miraglia et al, 
1997; Shai et al, 2003), adult and pediatric brain tumors, or a variety of morphologically defined 
glioma subtypes (van den Boom et al, 2003). These studies confirmed that morphological 
differences among gliomas are reflected at the mRNA level. In some cases gene expression profiles 
classify diagnostically challenging malignant gliomas in a manner that better correlates with 
clinical outcome than standard pathology does (Nutt et al, 2003; Shirahata et al, 2007).  
Several schemes for classifying GBM subtypes based on expression signatures have been proposed 
in the past several years (Freije et al, 2004; Nigro et al, 2005; Phillips et al, 2006; Verhaak et al, 
2010; Vital et al, 2010).  The first relevant study carried out by Phillips and colleagues divides a 
cohort of malignant gliomas, comprised of both WHO grade III and IV, into three molecular 
subtypes named Proneural, Proliferative, and Mesenchymal based on the key features of the 
molecular signatures associated with each group. The Proneural subtype is defined by genes 
implicated in neurogenesis. It is associated with better outcome than either of the other two tumor 
subtypes. In contrast, the Proliferative and Mesenchymal gene signatures are defined by 
proliferation- and extracellular matrix/invasion-related genes respectively, and are both associated 
with poor outcome. GBMs with Proliferative signatures have an elevated MIB-1 index in tumor 
cells, whereas GBMs of the Mesenchymal subtype show evidence for increased angiogenesis. The 
authors speculated that poor outcome of Proliferative and Mesenchymal tumors may be 
differentially associated with a high rate of tumor cell proliferation or angiogenesis, respectively. 
Prognostic significance of molecular subtype was validated in an independent cohort of 184 
gliomas of various histological types. Remarkably, nearly all WHO grade III tumors (65 out of 73 
gliomas) fell into the Proneural subgroup, along with a subset of glioblastomas occurring in 
younger patients with prolonged disease courses. Moreover recurrent tumors, although mostly 
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retaining their initial transcriptional subclassification, seemed to significantly shift their mRNA 
signatures towards the Mesenchymal profile. Of note, a recent work has identified a set of master 
regulator transcription factors, the most important of which are STAT3 and C/EBP-β, which seem 
to mediate the expression of the Mesenchymal phenotype and so enhance glioblastoma 
aggressiveness (Carro et al, 2010). 
An additional clustering analysis using transcriptional data obtained by the TGCA on 200 primary 
GBMs has established four distinctive GBM subtypes, namely Proneural, Neural, Classical, and 
Mesenchymal (Verhaak et al, 2010).  Significant similarities, but not an entirely overlap, were 
found between the mesenchymal and proneural phenotypes described in Phillips’ and Verhaak’s 
works. Unlike previous studies, the TCGA proneural subtype is not associated with improved 
prognosis in the TCGA data set consisting solely of grade IV astrocytoms, but it is in the validation 
of the data sets, containing lower-grade gliomas. Conversely, re-analysis of the TCGA data using 
Phillips’ molecular subtype designations confirmed a slightly more favorable prognosis of the 
“Phillips-proneural” relative to “Phillips-mesenchymal/proliferative” GBMs (Huse et al, 2011). 
Because of the tremendous amount of molecular data available for these tumors (TCGA, 2008) 
recurrent genomic aberrations in each molecular subtype were identified. 
The proneural subtype is more diffused in younger patients, as found in previous studies (Lee et al, 
2008; Phillips et al, 2006) and harbors frequent PDGFRA amplification and point mutations in 
IDH1, TP53 mutations and loss of heterozigosity and PIK3CA/PIK3R1 mutations. The proneural 
group shows high expression of oligodendrocytic development genes (such as PDGFRA, NKX2-2 
and OLIG2) and this signature contained several proneural development genes as well as DCX, 
DLL3, ASCL1 and TCF4 (Phillips et al, 2006). The neuronal subtype was characterized by the 
expression of neuron markers such as NEFL, GABRA1, SYT1 and SLC12A5. The classical 
subtype was characterized by frequent EGFR amplification and EGFRvIII mutations and a distinct 
lack of TP53 mutations and CDKN2A deletion. The mesenchymal subtype was typified by deletion 
of NF1, TP53, and PTEN genes and displayed expression of mesenchymal markers, such as CHIL3 
(also known as YKL40) and MET, as described elsewhere (Phillips et al, 2006). Moreover, higher 
overall necrosis, microvascular proliferation and inflammatory infiltrates are frequent in 
mesenchymal GBM, while necrosis typically lacks in the proneural subtype. 
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Using a proteomic analysis three proteomically-defined subclasses of GBM have been identified. 
These subclasses are characterized by protein- and phosphorylation-level signaling abnormalities in 
the EGFR, PDGFR, and NF1 pathways and correspond to classical, proneural, and mesenchymal 
subtypes of GBM, respectively (Brennan et al, 2009). 
Analysis of epigenetic changes performed by TCGA on GBMs identified a distinct subset of 
samples with characteristic promoter methylation alterations, indicating the existence of a G-CIMP 
phenotype (Noushmehr et al, 2010). G-CIMP tumors were mainly secondary or recurrent GBMs 
and were tightly associated with IDH1 mutations and displayed distinct copy-number alterations. 
Patients with G-CIMP positive tumors were younger at the time of diagnosis and survived longer 
than G-CIMP negative GBM patients. The integration of DNA methylation and gene expression 
data showed that G-CIMP positive tumors represented a subset of proneural tumors. At the end, G-
CIMP could be used to further refine the expression-defined groups into an additional subtype with 
clinical implications. 
Several studies have been published on the identification of glioma subtypes based on gene 
expression profiles, but no consensus gene expression profile in malignant gliomas reproducibly 
associates with patient outcome across independent datasets. 
However, the first gene expression profile based diagnostic test is currently being evaluated in two 
prospective, randomized clinical trials (Colman et al, 2010).  A 9-gene profile (AQP1, CHI3L1, 
EMP3, GPNMB, IGFBP2, LGALS3, OLIG2, PDPN, and RTN1) predictive of clinical outcome 
was identified for the development of a qRT-PCR assay performed on FFPE samples. On the basis 
of the logistical difficulties in obtaining fresh frozen tumors for DNA microarray based assays, 
such an assay is absolutely critical for successful clinical implementation with FFPE GBMs, which 
constitute the vast majority of clinical samples. In summary, molecular sub-typing has now the 
potential to become a readily implemented clinical test that may guide future treatment decisions. 
 
1.1.5 Brain tumor therapy 
1.1.5.1 Glioma diagnosis 
Patients with a malignant glioma may present a variety of symptoms including headache, confusion 
and loss of memory, neurological deficits and personality changes. The diagnosis of malignant 
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gliomas is usually made by magnetic resonance imaging (MRI), computer tomography (CT) or 
positron emission tomography (PET). The images typically show an enhancing mass surrounded by 
edema. Glioblastomas frequently have central areas of necrosis and more extensive peritumoral 
edema than that one associated with anaplastic gliomas. 
 
1.1.5.2 Glioma prognosis 
Despite decades of research and clinical trials, life expectancy for glioma patients has not improved 
considerably and is only about 2-3 years for anaplastic astrocytoma and 15 months for glioblastoma 
(Stupp et al, 2005). There are several reasons why it has been so difficult to find new effective 
therapies against glioma. First, drug delivery is limited by the blood-brain-barrier impediment and 
the distorted glioma vessels. Second, the invasive nature of gliomas makes the complete surgical 
resection of the tumor impossible. Third, tumor cells have also a strong inherent propensity for 
malignant progression and some cells, supposedly the cancer stem cells, are resistant to therapy 
(Bao et al, 2006). Lastly, over-expression of proteins involved in DNA repair machinery could 
cancel the effects of radio- and chemotherapy. 
 
1.1.5.3 Treatment 
The standard treatment for gliomas is the surgical resection, radiotherapy and chemotherapy using 
alkylating agents. The size and localization of the tumor is important for the possibility to perform 
optimal surgery. Due to their invasive growth, gliomas indeed are impossible to resect completely. 
Surgical elimination of the tumor reduces the symptoms caused by mass effect and seems to give a 
modest survival advantage to the patient. 
For patients with glioblastoma, the median survival from time of diagnosis is about three months 
without treatment. After treatment with surgery and postoperative temozolomide and radiotherapy, 
the survival increases to 14.6 months (Stupp et al, 2007). MGMT is an important repair enzyme 
that contributes to resistance to temozolomide. MGMT methylation silences the gene, decreasing 
DNA repair activity and increasing the susceptibility of the tumor cells to temozolomide. 
Treatment with temozolomide in glioblastoma patients with MGMT promoter methylation 
prolonged the survival to 2 years (Hegi et al, 2005). 
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Several approaches have been used to target individual signaling molecules involved in 
gliomagenesis. Particular interest has focused on inhibitors of RTKs and their downstream 
effectors, and on inhibitors of angiogenesis. 
EGFR is one of the most widely expressed RTK in human gliomas, so several EGFR inhibitors 
have been developed (Castillo et al, 2004). Gefitinib (ZD1839, Iressa™) (Rich et al, 2004) and 
erlotinib (Tarceva®) (Prados et al, 2006) have been investigated in recurrent gliomas with limited 
activity. An alternative approach has been developed based on a vaccination strategy against the 
constitutively activated EGFRvIII (Sampson et al, 2008). CDX-110™ is a peptide-based vaccine 
that targets the tumor specific mutated segment of EGFRvIII and it is currently in phase II/III 
randomized studies with radiation and temozolomide.  
Therapies directed towards the PDGFR pathway include many different putative targets (Grossman 
et al, 2001; Kilic et al, 2000). Imatinib (Gleevec®), a tyrosine kinase inhibitor specific for Abl 
kinase, c-KIT and PDGFR, has been demonstrated to have only limited anti-tumor activity in 
patients with recurrent malignant glioma (Raymond et al, 2008). PDGF antagonists might target the 
pericytes to preferentially block angiogenesis in established tumors (Sennino et al, 2007). 
Since angiogenesis is a hallmark of malignant glioma and affects drug delivery, anti-angiogenic 
treatment could be of value in combination with already existing treatment modalities. The VEGF 
signalling pathway is the cornerstone in angiogenesis, so most anti-angiogenic therapies towards 
target VEGF or VEGFR. Bevacizumab (Avastin®) is a humanised anti-VEGFA mAb. Promising 
results from a phase II study with bevacizumab in combination with irinotecan was reported in 
patients with recurrent high-grade glioma (Vredenburgh et al, 2007). However, there are emerging 
problems with both developing treatment-resistance and adverse effects associated with anti-VEGF 
therapy such as disturbance of VEGF-dependent physiological functions and homeostasis in the 
cardiovascular and renal systems, wound healing and tissue repair. This promoted the search for 
novel antiangiogenic therapies. VEGF-trap (aflibercept) is a soluble VEGF receptor binding 
VEGF-A, -B, and PDGF and has been shown to be effective in both initial and advanced phase of 
tumor development in a preclinical tumor model (Gomez-Manzano et al, 2008). This molecule is 
now in phase II trial in recurrent glioma that is not responding to temozolomide. Cediranib 
(AZD2171, Recentin™) is a RTK inhibitor of Pan-VEGFR 1-3, PDGFR and c-KIT. It is currently 
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in phase III clinical study in recurrent glioblastoma where patients are randomised between 
treatment with cediranib alone, cediranib in combination with lomustine (an alkylating agent) or 
lomustine with placebo. Using MRI, it is also shown that cediranib normalizes tumor vessels in 
glioblastoma patients and alleviates edema (Batchelor et al, 2007). Other VEGFR inhibitors that 
may be active against malignant glioma include the VEGFR/PDGFR inhibitors vatalanib (PTK 
787), pazopanib (GW 786034), sorafenib, and sunitinib; the VEGFR/EGFR inhibitor vandetanib 
(ZD6474); the adnectin-based CT 322; and the VEGFR/c-Met kinase inhibitor XL 184 (Norden et 
al, 2008). 
A great amount of signaling pathways and potential targets in malignant glioma has been 




Figure 2. Major signaling pathways in malignant gliomas and the corresponding targeted agents in 
development for glioblastoma. Adapted from Wen and Kesari, 2008. 
 
It is naive to believe that there will be one single treatment to cure all gliomas; rather the 
combination of multiple treatment strategies will have the best effect. Possibly, future patients will 
be given selected and individually targeted treatments based on the expression/mutation analysis of 
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that particular patient’s tumor. Ideally, treatment could be tailored to achieve the highest possible 
efficacy depending on the expression of growth factors and mutated genes. Strong efforts are made 
to effectively target tumor stem cells that will be discussed in the next chapter. These cells are 
believed to survive both radiation and chemotherapy, and can generate new tumor cells during 
recurrence. 
 
1.2 Cancer stem cells in solid tumors 
Tumors are composed of a heterogeneous population of cells that exhibit different states of 
differentiation and proliferation capacity. At least two models have put forward to account for 
heterogeneity: the “cancer stem cell” (Bonnet & Dick, 1997; Reya et al, 2001) and the “clonal 




Figure 3. Cancer stem cells and clonal evolution models. 
(a)In a normal tissue the cellular hierarchy comprising stem cells, which progressively generate more 
restricted progenitor cells and ultimately all the mature cell types that constitute the tissue. (b) In the clonal 
evolution model all undifferentiated cells have similar tumorigenic capacity. (c) In the cancer stem cell 
model, only the CSC can generate a tumor, based on its self-renewal properties and proliferative potential. 
(d) The two tumor models are not mutually exclusive- Initially, tumor growth is driven by a specific CSC 
(CSC1). With tumor progression, another distinct CSC (CSC2) may arise due to clonal evolution of CSC1. 
This may result from the acquisition of an additional mutation or epigenetic modification. This more 






The “cancer stem cell” hypothesis proposes that the growth and progression of many tumors are 
driven by a small subpopulation of cancer cells with stem-like features. These cells share important 
properties with normal tissue stem cells, including self-renewal (by symmetric and asymmetric 
division) and differentiation capacity, albeit aberrant. This implies that many cancers are 
hierarchically organized similarly to normal tissues. Just as normal stem cells differentiate into 
phenotypically diverse progeny with limited differentiation potential, CSCs also differentiate into 
phenotypically non-tumorigenic cells that compose the bulk of the cells within a tumor. The CSC 
model posits that differences in tumorigenic potential among cancer cells from the same patient are 
largely epigenetically determined, because it is unlikely that only rare cancer cells have a genotype 
permissive for extensive proliferation. However, there is no direct evidence that tumorigenic cells 
differ from non-tumorigenic cells as a result of epigenetic rather than genetic differences 
(Shackleton et al, 2009).  
In the “clonal evolution” model all the cells have similar tumorigenic capacity. The mutated cells 
with a growth advantage are selected and expanded, with the cells in the dominant clone having a 
similar potential for generating tumor growth. The clonal evolution model postulates that genetic 
and epigenetic changes occur over time in individual cancer cells. If such changes confer a 
selective advantage they will allow individual clones of cancer cells to out-compete with other 
clones. Clonal evolution can lead to genetic heterogeneity, conferring phenotypic and functional 
differences among the cancer cells within a single patient (Shackleton et al, 2009). 
It is important to note that the clonal evolution and the cancer stem cell model are not mutually 
exclusive in cancers that follow a stem cell model, as cancer stem cells would be expected to 
evolve by clonal evolution (Barabe et al, 2007). Thus, if a mutation conferring self-renewal or 
growth properties advantages occurs, a more dominant cancer stem cell may emerge among the 
others. For example, the leukemic stem cells that maintain chronic myeloid leukemia despite 
imatinib therapy would be selected by clonal evolution to develop imatinib resistance mutations 
over time (Shah et al, 2007).  
The first evidence for the existence of CSCs came from acute myeloid leukemia (Bonnet & Dick, 
1997; Lapidot et al, 1994), in which a rare subset of cells comprising 0.01-1% of the total 
population could induce leukemia when transplanted into immunodeficient mice. These concepts 
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and experimental approaches were then applied to solid tumors such as breast (Al-Hajj et al, 2003), 
brain (Singh et al, 2004) and colon (Ricci-Vitiani et al, 2007) cancers. 
Most studies on cancer stem cells follow a common scenario: a marker or a combination of markers 
is found to be expressed in a heterogeneous fashion in a certain tumor type. On the basis of this 
marker heterogeneity or using markers of normal stem cells of the same organ, subpopulations of 
cells are sorted from primary tumors and transplanted into immunodeficient mice by limiting 
dilution; then, the tumor growth is evaluated some weeks or months later. Different capacity for 
tumor initiation between tumor cell subsets can be interpreted as evidence for the presence of CSCs 




Figure 4. Testing the Cancer Stem Cell Model. 
The tumor is dissociated into single cells using conditions optimized to maximize the preservation of cell 
viability and surface marker expression. The cells are sorted by flow cytometry using specific cell surface 
markers. The tumorigenicity of all cells is tested using xeno-transplantation assays. Adapted from Shackleton 




According to the CSC model only a specific subset of cancer cell population should be able to 
sustain in vivo tumor growth, whether all other subsets should not. The transplanted tumors contain 
mixed populations of tumorigenic and non-tumorigenic cancer cells, thus recapitulating at least 
some of the heterogeneity of the parental tumor. However, the most convincing demonstration of 
CSC identity comes from serial transplantation of a cellular population into the animal model, 
which is the only true demonstration of self-renewal ability of a cancer cell.  
The frequency of cancer stem cells is highly variable between solid tumors of the same type. 
Recent mathematical analyses have further indicated that CSCs in advanced tumors may not occur 
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as a small fraction (Kern & Shibata, 2007). Extensive in vivo limiting dilution analyses are required 
to determine the frequency of CSCs within solid tumors and to prove enrichment (Bonnefoix et al, 
1996). This may eventually allows correlation between CSCs frequency, tumor grade and clinical 
outcome. It is also important to note that the nature of the xenograft model used and the site of 
transplantation influence the determination of stem cell frequency. The efficiency of human cell 
engraftment can be significantly influenced by the presence of residual immune effector cells in 
recipient mice (Quintana et al, 2008). The xenogeneic immune response that mice mount against 
human cells can reduce the ability of human cancer cells to engraft in mice, underestimating the 
frequency of human cancer cell with tumorigenic potential. On the other hand it is also clear that 
immune cells have a role in the progression of many tumors and this highly artificial animal model 
may not represent the true in vivo niche. The activity of tumor cells can also be influenced by an 
altered vascular environment, which creates the stem cell niche. Thus, the development of 
orthotopic transplantation assays is crucial. 
The concept that cancer growth can be sustained by cancer stem cells leads to the necessity of new 
and more effective antitumor treatments. According to the CSC model, therapeutic approaches that 
do not eradicate the CSC compartment are likely to achieve little success; they might kill the 
majority of tumor cells and induce temporary regression of gross tumor lesions but fail to prevent 
disease relapse and metastatic dissemination (Figure 5). 
 
1.2.1 Neural Stem Cells 
Neural stem cells (NSCs) are multipotent cells within the brain capable of self-renewal and 
differentiation into all major cell types of the central nervous system (neurons, astrocytes and 
oligodendrocytes) (Mayer-Proschel et al, 1997; Rao et al, 1998) (Figure 5). During development 
NSCs are found in the ventricular zone of the central nervous system. In the adult brain, NSCs are 
primarily restricted to two areas: the subependymal zone of the lateral ventricles and the 
subgranular zone of the dentate gyrus within the hippocampus. In the hippocampus, NSCs integrate 
functionally into the granule cell layer (Cameron & McKay, 2001). In the rodent brain, progeny 
from neural stem cells of the subventricular zone migrate along the rostral migratory stream to the 
olfactory bulb to differentiate into local interneuron (Lois et al, 1996; Luskin, 1993). In the human 
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brain, migration of neuroblasts toward the olfactory bulb may occur via alternate routes (Curtis et 
al, 2007; Sanai et al, 2004). Persistence of NSCs in the adult reflects their role in endogenous repair 
mechanisms and maintenance of normal brain functions. Adult neurogenesis is likely to have a 




Figure 5. Resistance Mechanisms in Glioma Cells. 
Normal neural stem cells self-renew and give rise to multipotential progenitor cells that form neurons, 
oligodendroglia, and astrocytes. Glioma stem cells arise from the transformation of either neural stem cells or 
progenitor cells (red) or, less likely, from differentiation of oligodendrocytes or astrocytes (thin red arrows) 
and lead to malignant gliomas. Glioma stem cells are relatively resistant to standard treatments such as 
radiation and chemotherapy and lead to re-growth of the tumor after treatment. Therapies directed at stem 
cells can deplete these cells and potentially lead to more durable tumor regression (blue). 
  
1.2.3 Glioma stem cells (GSCs) 
The presence of stem cells in brain tumors has been demonstrated in several studies (Galli et al, 
2004; Hemmati et al, 2003; Ignatova et al, 2002; Singh et al, 2003; Singh et al, 2004; Yuan et al, 
2004). However the isolation of brain tumor cells with tumorigenic capacity, tested in vivo using 
the xeno-transplantation assay, was initially reported independently by two groups (Galli et al, 
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2004; Singh et al, 2004). Although reaching at similar conclusions, they used different approaches 
for isolating brain tumor stem cells: the cell sorting based on selection for the cell surface marker 
CD133 (Singh et al, 2004) and the neurosphere assay (Galli et al, 2004). 
 
1.2.3.1 Isolation of glioma stem cells using cell surface markers 
The first prospective in vitro and in vivo identification and characterization of a putative CSC from 
human brain tumors was based on cell sorting for the neural stem cell surface marker CD133 
(Singh et al, 2003; Singh et al, 2004). Uchida and colleagues sorted human fetal brain cells for 
CD133 expression highly enriching for stem cell properties in vitro and in vivo (Uchida et al, 
2000). Then CD133 was used to sort fresh human brain tumors. In vitro, CD133-positive cells 
formed clonogenic neurosphere colonies, proliferated and could be induced to differentiate into 
mature neural cell lineages that were characteristic of the mature lineages seen in the patient’s 
original tumor. Moreover CD133-positive brain tumor cells were highly enriched for tumor 
initiating activity in vivo. As few as 100 CD133-positive cells were able to initiate fatal infiltrative 
tumors in immunocompromised NOD/SCID mice after orthotopic transplantation. Injection of 
100000 CD133-negative cells did not lead to tumor formation, although viable human tumor cells 
could be identified in the mouse brains four months after transplantation, suggesting that these cells 
were viable, but were no longer able to initiate tumor formation. Serial passage of CD133-positive 
cells re-isolated from the primary transplant and injected into secondary recipient was also shown. 
It is important to note that sorting for CD133 enriches for cancer stem cells but does not 
definitively identify them. Furthermore several studies have questioned the utility of CD133 in the 
isolation of glioma stem cells. Hence, a number of cell surface markers have been proved useful for 
the isolation of GSCs, including CD15 (Son et al, 2009), CD44 (Anido et al., 2010), Integrin-α6 
(Lathia et al, 2010), ABCB5 as well as Hoechst33342 exclusion by the side population cells 
(Bleau et al, 2009; Harris et al, 2008). Notably, none of these markers are exclusively expressed by 
the CSCs and in all the tumor samples, highlighting the necessity of additional and more specific 





1.2.3.2 Isolation of glioma stem cells using the neurosphere assay 
In serum-free culture, in the presence of mitogens including epidermal growth factor (EGF) and 
fibroblast growth factor (FGF), human brain tumor stem cells can be grown as single cell–derived 
colonies, namely neurospheres (Galli et al, 2004; Hemmati et al, 2003; Ignatova et al, 2002; Singh 
et al, 2003; Yuan et al, 2004). The neurosphere assay was initially used by Reynolds and Weiss in 
1992 to isolate neurospheres from the mouse striatum (Reynolds & Weiss, 1992) and was 
subsequently used to successfully enrich tumor-initiating cells from brain tumors. This assay is 
currently used as the standard in vitro method for identifying the presence of stem cells derived 
from both tumor and non-tumor tissues (Chaichana et al, 2006; Reynolds & Rietze, 2005; Vescovi 
et al, 2006). Similar sphere-forming assays are also used in other stem cell systems, including skin 
(Toma et al, 2001) and breast (Al-Hajj et al, 2003). 
The selective serum-free conditions, in which the neurosphere assay is carried out, allow the stem-
like cells to continually divide and form multipotent clonal spheres, while the more differentiated 
cells incapable of self-renewal and multipotency die off with serial passages (Chaichana et al, 2006; 
Reynolds & Rietze, 2005) (Figure 6). 
 
 
Figure 6. Isolation, perpetuation and differentiation of brain tumor stem cells in culture. 
The neurosphere assay in a serum-free culture system that allows the isolation of stem cells based on their 
exclusive and extensive self-renewal potential. Adapted from Vescovi et al. 2006. 
 
 
Notably, on mitogen removal and in addition of serum the cells can be differentiated into neurons, 
astrocytes and oligodendrocytes. The assay thus provides culture conditions allowing competent 
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cells to exhibit the cardinal stem cell property of self-renewal over an extended period of time, then 
generating a large number of progeny that can differentiate into the primary cell types of the tissue 
from which they were obtained (Louis et al, 2008). Neurosphere initiating cells isolated from 
human GBM have stem-cell characteristics: extensive self-renewal, multipotency and the capacity 
to initiate new tumors that recapitulate the histological features of the parental tumor, when 
transplanted into the brain of immunodeficient mice (Galli et al, 2004).  
Most importantly, in vivo studies have shown that neurosphere formation is a significant predictor 
of clinical outcome in glioma patients, independent of Ki67 proliferation index, and is a robust, 
independent predictor of glioma tumor progression (Laks et al, 2009). 
Hence the neurosphere assay has become the method of choice to study neural and brain tumor 
stem cell populations in vitro. However, it is associated with some limitations. 
Neurospheres are composed by a heterogeneous cell population that consists of stem cells, together 
with progenitors and more differentiated cells (Reynolds & Weiss, 1996; Suslov et al, 2002). Only 
the stem cells can exhibit extended self-renewal over serial passages, while the progenitor cells may 
not be able to form neurospheres for more than six passages and the terminally differentiated cells 
are not able to form any sphere. A true separation of stem cells and progenitor cells in the 
neurosphere remains problematic. However, recent studies have found that spheres >2 mm in 
diameter show high proliferative potential and multilineage differentiation over time, whereas 
smaller spheres have limited proliferation potential and typically only differentiate into cells with 
an astrocytic phenotype (Liu et al, 2009; Louis et al, 2008). Thus, larger neurospheres (>2 mm) are 
more likely to be derived from stem cells, rather than from progenitor cells with limited 
proliferative and differentiating capacities (Louis et al, 2008). 
Besides being used to enrich CSCs, neurosphere assays are also widely adopted to estimate stem 
cell frequency by counting secondary neurosphere formation, however an estimation of stem cell 
frequency based on the number of secondary neurospheres could significantly overestimate stem 
cell number because of the existence of confounding spheres derived from progenitors (Reynolds & 
Rietze, 2005). The in vivo limiting dilution assay made through injection of a progressive lower 
number of cells in the mouse brain, could be a more accurate assay to calculate the stem cell 
frequency in the neurosphere. Moreover, the transplantation of individual glioma spheres into 
28	  
	  
mouse brains, and the serial transfer of the xenograft tumors through mice for several passages 
could demonstrate the in vivo self-renewal ability of CSCs. 
The ability to grow human brain tumor cells as neurospheres is variable. Glioblastoma cells are 
most easily grown in these conditions, but other types of brain tumors, such as medulloblastoma 
and ependymoma, can be grown only for short periods in neurosphere conditions (Taylor et al, 
2005). 
Nevertheless, application of serum-free growth conditions to glioblastoma-derived cells has enabled 
growth of cell lines that retain the same genotype of the patient’s primary tumor (Vik-Mo et al, 
2010), and which show stable stem cell properties in vitro and more faithful generation of models 
of the disease after xenotransplantation in vivo (Lee et al, 2006). These methods clearly show the 
advantages of serum-free based culture methods for studying human brain tumor cells, and suggest 
that serum-based cultures have limited utility. 
 
1.2.4 Cell of origin of gliomas 
The term cancer stem cell does not imply that this tumor cell derives from a normal stem cell. It is 
not yet clear whether cancer-initiating events occur in NSCs, progenitors or differentiated cells. 
However, NSCs are reasonable candidates as cell of origin of brain tumor stem cells, because their 
lifespan can easily induce the acquisition of multiple gene abnormalities necessary for 
tumorigenesis (Dalerba et al, 2007; Hanahan & Weinberg, 2000). Currently, in mouse brain tumors 
experimental evidences are indicating stem cells and progenitor cells as well as more differentiated 
cells as cell of origin (Bachoo et al, 2002; Holland et al, 2000; Liu et al, 2011; Stiles & Rowitch, 
2008; Uhrbom et al, 2002) (Figure 5). It is also of relevant note that brain tumors of different 
phenotypes, in different locations and with different genetic mutations may have different cell of 
origin (Stiles & Rowitch, 2008). Identifying the cell of origin of brain tumor may be important for 
several reasons. The particular cell in which an oncogene is expressed may determine the 
subsequent phenotype and resulting aggressiveness of the tumor, suggesting that different 





1.2.5 Glioma stem cell niche 
Stem cell biology is strongly supported by a specialized microenvironment or stem cell niche. Stem 
cell niches are complex dynamic entities that actively regulate stem cell function (Scadden, 2006), 
in particular their self-renewal and fate. Calabrese and colleagues demonstrated that stem cells 
from various brain tumors, including glioblastoma, are maintained within vasculature niches that 
mimic the neural stem cell niche (Calabrese et al, 2007). Notably, co-transplanting brain tumor 
stem cells and endothelial cells into immunocompromised mice, the initiation and growth of tumors 
in the brain were accelerated by the endothelial derived factors. 
Brain tumor stem cells seem to have potent angiogenic properties and can recruit vessels during 
tumorigenesis. It was shown that CD133-positive human glioblastoma CSCs produced high level 
of VEGF and formed highly vascular and hemorrhagic tumors in the brains of 
immunocompromised mice. Furthermore, treating CD133-positive cells with bevacizumab blocked 
their ability to induce endothelial cell migration and tube formation in culture, and initiate tumors 
in vivo (Bao et al, 2006). Moreover it was observed that glioblastoma stem cells directly 
differentiate into endothelial cells lining tumor vessels (Ricci-Vitiani et al, 2010; Wang et al, 
2010).  As well as regulating stem cell proliferation and cell-fate decisions, niches also have a 
protective role defending stem cells from environmental insults (Moore & Lemischka, 2006).  
 
1.2.6 Implications of glioma stem cells in the therapy 
From a clinical perspective, the cancer stem cell concept has significant implications, as these cells 
need to be eradicated in order to provide long-term disease free survival (see Figure 5). Cancer 
stem cells are thought to be resistant to chemotherapy and targeted therapy, through active 
mechanisms. They often express higher level of drug-resistance proteins such as ABCG2 and 
ABCG5 and multidrug resistance protein 1 (MDR1) transporters. Human CD133-positive 
glioblastoma cells are resistant to a variety of chemotherapeutic agents and to radiotherapy (Eramo 
et al, 2006; Kang & Kang, 2007). 
The gene profile of CD133-positive cells exhibits a high expression level of anti-apoptotic genes 
and chemotherapy resistance genes, such as breakpoint cluster region psuedogene 1 (BCRP1) and 
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O6-methylguanine-DNA-methyltransferase (MGMT), rendering these cells resistant to many 
commonly used chemotherapeutic agents (Liu et al, 2006; Salmaggi et al, 2006). 
CD133-positive cells play a crucial role also in radiation therapy failure. In a study conducted by 
Bao et al., the CD133-positive cells showed a more potent activation of DNA damage checkpoint 
mechanisms. This repair mechanism has been shown to be targetable through pharmacologic 
inhibition of the checkpoint kinases Chk1 and Chk2, which renders the CD133 glioblastoma cells 
more radiosensitive (Bao et al, 2006). 
Glioma stem cells might be further protected from conventional therapies by factors within the 
vascular niche. Treatments that disrupt aberrant vascular stem cell niches could therefore result 
efficient against gliomas, because they might also function to disrupt stem cell maintenance. 
Calabrese and colleagues showed that treating glioblastoma-bearing mice with bevacizumab 
depleted tumor blood vessels and caused a dramatic reduction in the number of glioblastoma stem 
cells and the growth rate of the tumor (Calabrese et al, 2007).  
Also pathways regulating neural stem cell proliferation and differentiation might be targeted in 
brain tumor treatment. Promotion of tumor stem-cell differentiation may be an important strategy 
for treatment of brain tumor stem cells. Vescovi and collegues (Piccirillo et al, 2006) have shown 
that BMPs, which normally induce astrocyte differentiation from normal neural precursors, have 
been shown to promote glioblastoma cell differentiation in vitro and in vivo, reducing stem cell 
tumorigenicity in vivo. Another possibility is to target the process of CSC differentiation into 
endothelial cells in the tumor (Ricci-Vitiani et al, 2010; Wang et al, 2010). 
Signaling pathways that regulate stem-cell self-renewal and proliferation, such as Notch, Shh, and 
Wingless pathways are potentially important targets in the therapy against glioma stem cells.  
 
1.3 CD133 
CD133 is considered a marker of stem cells in diverse normal tissues and cancer types. Several 
studies demonstrated the utility of CD133 in the enrichment of population of cells with stem-like 
properties in normal and tumor tissues, but there is also a large body of evidence narrowing down 
its use as a stem cell marker. In this section all the relevant findings concerning CD133 as 





1.3.1 Structure of CD133 
CD133 (also known as prominin-1) was the first identified member of the prominin family, 
composed of pentaspan membrane proteins. It is an 865 aminoacid protein that contains five 
transmembrane domains, an extracellular N-terminus, a cytoplasmic C-terminus, and two large 




Figure 7. Schematic diagram of CD133 structure. The five transmembrane structure of the CD133 
molecule including the aminoacid lengths of the intra- and extracellular loops and the number of predicted 
trypsin cleavage sites. The actual numbers and positions of glycosylation sites are as yet unknown. Adapted 




CD133 gene (PROM1) is conserved throughout the animal kingdom. The human PROM1 gene is 
mapped on chromosome 4p15 (Corbeil et al, 1998; Miraglia et al, 1997). In addition to the rodent 
and human, CD133 and predicted CD133-like molecules have been identified in worm, fly, fish 
and chicken (Fargeas et al, 2003; Roper et al, 2000; Weigmann et al, 1997). In humans, 
transcription of CD133 is driven by five tissue-specific alternative promoters resulting in the 
formation of differentially spliced mRNA isoforms which are further regulated by methylation 
status and result in CD133 variants with distinct cytoplasmic C-terminal domains (Fargeas et al, 
2004; Kemper et al, 2010; Shmelkov et al, 2004). 
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1.3.2 Cellular localization of CD133 
At subcellular level, CD133 selectively marks plasma membrane protrusions such as the microvilli 
and the primary cilia that are located in the apical domain of polarized epithelial cells (Corbeil et al, 
2000; Dubreuil et al, 2007; Weigmann et al, 1997). Moreover, if the protein is expressed 
exogenously in non-epithelial cells such as CHO cells, CD133 preferentially localizes in 
lamellipodia and filopodia structures (Corbeil et al, 2001) In hematopoietic stem cells CD133 is 
localized on the protrusions of migratory polarized cells together with adhesion molecules (Bauer et 
al, 2008). Its specific localization on these plasma membrane domains is related to the presence of 
cholesterol directly bound by CD133 and specific membrane lipid domains named "Lubrol rafts" 
(Marzesco et al, 2009; Roper et al, 2000). This membrane micro-domains differ from that found in 
non-protruding area of the plasma membrane, as demonstrated biochemically using mild detergent 
and morphologically by co-localization with the ganglioside GM1 (Janich & Corbeil, 2007).  
Recent studies have reported a cytoplasmic rather than an exclusive plasma membrane localization 
of CD133 (Corbeil et al, 2000; Immervoll et al, 2008). In particular Bauer et al demonstrated that 
human hematopoietic stem cells contain an important intracellular pool of CD133, primarily located 
in membrane vesicles within multivesicular bodies (Bauer et al, 2011). In human glioblastoma cell 
lines cultured in serum-free conditions or in presence of serum, CD133 is accumulated in 
intracellular structures such as the endoplasmic reticulum and the Golgi apparatus (Campos et al, 
2011). Moreover, an asymmetric segregation of CD133 was observed in mitotic glioma stem cells, 
almost always associated with Numb asymmetry (Lathia et al, 2011). 
 
1.3.3 The biological function of CD133 
Little is known about the biological functions of CD133. The specific localization of CD133 in the 
apical membranous protrusions of the microvilli of epithelial cells may suggest that it is involved in 
the maintenance of apical–basal polarity and cell migration (Corbeil et al, 2001; Kosodo et al, 
2004). A functional role as an “organizer” of plasma membrane topology can also been ascribed to 
CD133 (Corbeil et al, 2001; Zacchigna et al, 2009). Interactions between CD133 and cholesterol 
within such novel membrane microdomains suggest that CD133 might be important for maintaining 
an appropriate lipid composition within the plasma membrane (Roper et al, 2000). 
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Although tightly associated with plasma membrane, CD133 is released into numerous physiological 
body fluids including urine, saliva, seminal fluids and cerebrospinal fluids in association with small 
membrane vesicles (Huttner et al, 2005; Huttner et al, 2008; Marzesco et al, 2005). Remarkably, 
CD133-containing membrane vesicles appeared to be up-regulated in patients affected by epilepsy 
or glioblastoma, suggesting that neural stem cells and putative cancer stem cells might release them 
as well (Huttner et al, 2005; Huttner et al, 2008). Small CD133-containing membrane particles were 
also found in the ventricular fluid within the developing mouse neural tube, and their appearance 
coincided with the regression of microvilli and the formation of large pleomorphic protuberances 
on the embryonic neuro-epithelium (Marzesco et al, 2005). It is important to point out that such 
vesicles are budding from the tip of a microvillus or a primary cilium by a molecular mechanism 
involving cholesterol-dependent membrane microdomains (Corbeil et al, 2010; Marzesco et al, 
2009). Interestingly such release occurs during and after the differentiation of Caco2 cells and 
human hematopoietic stem cells (Bauer et al, 2011) or, in vivo, of neural progenitor cells (Marzesco 
et al, 2005). These findings highlighted a potential functional role of CD133, supporting the 
hypothesis that its expression may sustain a stem cell phenotype. CD133-containing lipid rafts may 
host key determinants or players necessary to maintain stem cell properties; upon their release a cell 
might become committed to differentiation (Bauer et al, 2008; Bauer et al, 2011). In agreement 
with this, it has been demonstrated that neurogenic cell divisions of neural progenitors and 
asymmetric division of glioblastoma stem cells, involve an asymmetric distribution of CD133 
(Kosodo et al, 2004; Lathia et al, 2011). 
Notably, loss of CD133 due to a frameshift mutation in the PROM1 gene results in a truncated 
protein that is no longer transported to the cell surface, and is associated with retinal degeneration 
(Maw et al, 2000). This is possible because of impaired generation of the invaginations and/or 
impaired conversion of the invaginations to disks, suggesting a role of CD133 in the formation of 
plasma membrane protrusions.  
 
1.3.4. CD133 as normal stem cell marker 
CD133 alone or in combination with other markers, has been used to identify stem cells from a 
variety of tissues. However, to determine whether CD133 is a valid marker for stem cells in a 
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tissue, it is crucial to understand the biology of the cells expressing the protein and distribution 
pattern of the cells within the tissue. 
On human bone marrow cells, the CD133 antibody recognizes a CD34-bright subset of 
hematopoietic stem cells and early progenitor cells that engraft successfully in a fetal sheep 
transplantation model and exhibit long-term repopulating potential (Miraglia et al, 1997; Yin et al, 
1997). CD133 appears to be a reliable marker for the isolation of neural stem cells (as described in 
the paragraph “Isolation of glioma stem cells using cell surface markers”). In single cells derived 
from fresh human fetal brain tissue, CD133(+) CD34(−) CD45(−)-sorted cells initiated neurosphere 
cultures, which could differentiate into both neurons and glial cells and exhibited self-renewal 
potential. Upon transplantation into brains of immunodeficient neonatal mice, the cells showed 
potent engraftment, proliferation, migration, and neural differentiation (Uchida et al, 2000). In 
adult human prostate, CD133 identifies stem cells able to reconstitute prostatic-like acini when 
grafted into immunocompromised mice (Richardson et al, 2004). In the stomach, duodenum, and 
colon, cells at the basis of the crypts - where stem cells are likely to reside - expressed CD133 at 
their apical/endoluminal surface, suggesting that stem cells may be among the CD133(+) cells in 
these organs (Immervoll et al, 2008). CD133 also marks the bone marrow-derived circulating 
endothelial progenitors that participate in tumor angiogenesis (Shaked et al, 2006). On the other 
hand, it appears clear that not all CD133-expressing cells are stem cells. Several studies indicate 
that CD133 is expressed in differentiated epithelial cells in a variety of organs such as the pancreas 
(Immervoll et al, 2008; Lardon et al, 2008), liver, salivary gland and lachrymal glands, colon, 
stomach and duodenum, sweat glands, and uterus (Immervoll et al, 2008; Karbanova et al, 2008) 
and kidneys (Sagrinati et al, 2006). Furthermore using a knock-in LacZ reporter mouse 
(CD133lacZ/+) model, in which the endogenous CD133 promoters drive the expression of LacZ, 
the reporter gene LacZ was found expressed in differentiated epithelia in colon and other tissues 
(Shmelkov et al, 2008). These findings are consistent with a more recent study demonstrating that 
CD133 is expressed in a variety of developing and adult tissues in a mouse model with an inducible 
Cre, nuclear LacZ reporter allele knocked into the Prominin1 locus (Zhu et al, 2009). Taken 
together, these studies indicate that the overall expression of human CD133 is beyond the stem 
cells and it appears to be a general marker of apical or apico-lateral membrane of glandular 
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epithelia. Furthermore to date, no stem cell population from any tissue type can be prospectively 
isolated to clonal purity on the basis of a single marker. 
Furthermore it is of significance to consider that the expression of glycosylated epitopes of CD133 
(such as AC133 and AC141) have been used to define and isolate the various stem cell populations. 
Therefore it is possible that the expression of AC133 and AC141 antigens may not be synonymous 
of CD133 expression. Florek et al defined an antibody that recognized human CD133 
independently of glycosylation (αhE2), and found that CD133 antigen expression was retained in 
differentiated Caco2 cells and was present on the apical membrane of the proximal tubules of the 
adult kidney. A multiple tissue expression array showed that human CD133 mRNA was strongly 
expressed in several tissues including adult kidney, mammary gland, trachea, salivary gland, 
placenta, pancreas, digestive tract, and testes (Florek et al, 2005).  
 
1.3.5 CD133 as cancer stem cell marker 
Evidences for the existence of CD133-expressing cancer stem cell populations have been provided 
in numerous tumor types including leukemia (Bhatia, 2001), prostate cancer (Collins et al, 2005), 
colon cancer(O'Brien et al, 2007; Zhu et al, 2009), lung cancer (Eramo et al, 2008), hepatocellular 
carcinoma (Suetsugu et al, 2006), ependymoma (Taylor et al, 2005), melanoma (Monzani et al, 
2007), ovarian cancer (Ferrandina et al, 2009), medulloblastoma and glioblastoma (Singh et al, 
2004). These CD133 expressing cancer cells all exhibited features of stem cells such as self-
renewal, potency in proliferation and capacity to initiate tumors after transplantation into 
immunodeficient mice. 
 
1.3.6 CD133 as marker of glioma stem cells 
With regard to brain tumors, Singh et al (Singh et al, 2003; Singh et al, 2004) were the first to 
describe a CD133-positive tumor cell population, with stem cells characteristics, that is capable of 
self-renewal and exact recapitulation of the original tumor when transplanted into immunodeficient 
mouse brains (as described above).  
Quantitative analysis of CD133 positive cells by flow cytometry has generally found them to be 
present at low, and sometimes barely detectable, levels in human gliomas, glioma sphere cultures 
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and established glioma cell lines (Clement et al, 2009; Joo et al, 2008; Shu et al, 2008; Singh et al, 
2004; Wang et al, 2008), consistent with the assumption that CSCs are a rare cell population in 
solid tumors. However, some studies have reported exceptionally high CD133 positive (20%–60%) 
fractions in some human GBMs and/or glioma cell lines (Joo et al, 2008; Singh et al, 2004; Son et 
al, 2009), according to immunohistochemical findings demonstrating that many GBMs contain 
more than 25% CD133 positive cells (Zeppernick et al, 2008). 
 
1.3.6.1 Prognostic value of CD133 in glioblastoma 
Studies investigating the distribution and the prognostic value of CD133 have reported inconsistent 
findings (Beier et al, 2008; Christensen et al, 2008; Immervoll et al, 2008; Pallini et al, 2008; 
Rebetz et al, 2008; Thon et al, 2010; Zeppernick et al, 2008; Zhang et al, 2008). On one hand, a 
quantitative correlation of glioma grade with the presence of CD133 positive cells within tumors 
and a negative association between CD133 expression and patient survival, have been demonstrated 
in large cohorts of glioma patients. Opposite results were obtained by Christensen et al (Christensen 
et al, 2008) demonstrating no correlation between the presence of tumor cells expressing CD133, 
and both tumor grade and clinical outcome. 
It is noteworthy that CD133 antigen has been used to enrich for cancer stem cells using flow 
cytometry, but whether or not CD133 expression measured by mRNA and/or protein on 
immunoblotting or immunofluorescence identifies cancer stem cells is not yet clearly established. 
However, the association of CD133 mRNA and protein with poor prognosis has been reported in 
several studies (Metellus et al, 2011; Raso et al, 2011; Yu et al, 2010), including a very recent one 
that analyses the prognostic impact of CD133 mRNA in 48 glioblastomas (Metellus et al, 2011). 
To address the issue of the clinical relevance of CD133, we interrogated the in silico GBM patient 
databases, REMBRANDT and TCGA, and we found that CD133 mRNA does not correlate with 
patient survival, contrary to what was previously shown (Figure 8). This analysis made in hundreds 
of GBM specimens confirms that CD133 has no value as a prognostic marker in glioblastomas 






Figure 8. CD133 in GBMs is not predictive of patient survival 
Kaplan-Meier survival plot for glioblastoma patients with differential tumor CD133 expression calculated by 
TGCA (A) and REMBRANDT (B) database. The log-rank P-value for significance of difference of survival 
between groups was calculated as >0.05 in all cases. 
 
1.3.6.2 Limitations in the use of CD133 as glioblastoma stem cell marker 
A great source of inconsistency in experimental results may derive from the use of alternative 
antibodies recognizing different CD133 protein epitopes. The most widely used antibodies in 
CD133-related experiments are the CD133/1, directed against the AC133 epitope, and the 
CD133/2, directed against AC141 epitope. The AC133 and AC141 epitopes are both glycosylated 
and have distinct spatial locations (Miraglia et al, 1997; Yin et al, 1997), but their molecular nature 
and their locations on the CD133 protein have not been determined. Several reports have 
documented an overlap of the AC133 and AC141 positive cell populations (Corbeil et al, 2000; 
Florek et al, 2005; Yin et al, 1997), although currently there are no specific studies on the 
comparability of antibodies recognizing these two different epitopes. Indeed, immunohistochemical 
staining of AC133 and AC141 epitopes poses a special challenge leading some researchers to use 
alternative antibodies recognizing the CD133 protein. A recent study demonstrated the inconsistent 
CD133 detection when using different primary CD133 antibody clones in immunohistochemistry 
(Bidlingmaier et al, 2008; Hermansen et al, 2011).  
In addition, the glycosylated nature of the AC133 epitope has been questioned since CD133/1 
antibody can effectively detect bacterially expressed, unglycosylated CD133 (Kemper et al, 2010). 
Moreover, the exclusive detection of glycosylation-dependent epitopes does not exclude the 
expression of differentially or non-glycosylated CD133. Several studies have demonstrated that the 
AC133 and AC141 epitopes can be down-regulated independently on the CD133 mRNA (Corbeil 
38	  
	  
et al, 2000; Florek et al, 2005) and that the tissue distribution of CD133 mRNA is more widespread 
than expression of the AC133 epitope. CD133 is expressed in differentiated epithelial cells in a 
variety of tissues, though it has been used to identify normal stem cells and cancer stem cells in 
many of these organs (Shmelkov et al, 2008). 
Another matter of debate is the fact that the expression of CD133 is subjected to changes in the 
microenvironment cues. Indeed it has been demonstrated that CD133 expression is up-regulated by 
hypoxia (Griguer et al, 2008) and that it is finely regulated during the cell cycle progression of 
neural and embryonic stem cells (Sun et al, 2009). 
 
1.3.6.3 CD133-negative GSCs 
There are several lines of evidence to suggest the existence of CD133-negative glioma stem cells. 
First, CD133 is not detectable in many fresh GBM specimens (Beier et al, 2007; Joo et al, 2008; 
Son et al, 2009) and in established glioma cell lines, which can nonetheless form tumors in vivo 
(Son et al, 2009; Wang et al, 2008). 
Second, cells with stem cell characteristics and tumorigenic potential can be isolated from CD133-
negative gliomas as well as from CD133 positive tumors. Stem cells isolated from CD133-positive 
and -negative tumors may differ in terms of other phenotypic features, such as proliferation, 
invasiveness and expression profiles (Lottaz et al, 2010). A recent study based on gene expression 
profile analysis of CSC isolated from CD133-positive and CD133-negative gliomas, have led to the 
definition of two different types of glioma stem cells: Type 1 CSCs that are CD133 positive and 
grow as floating neurospheres and Type 2 CSCs which are CD133 negative and grow adherently. 
Interestingly, Type 1 cells were reminiscent of fetal neural stem cells and Type 2 cells genetically 
resemble adult neural stem cells (Lottaz et al, 2010). 
Third, both CD133-positive and CD133-negative cells isolated from the same tumor specimen can 
be cultured as neurospheres under serum free conditions, and both populations of cells are able to 
self-renew and to initiate and propagate tumors upon xenotransplantation. Indeed, CD133-negative 
cells are able to generate CD133 positive progeny in vitro and in vivo (Chen et al, 2010; Wang et al, 
2008). Chen et al. recently demonstrated the existence of three different, but coexisting types of 
glioma stem cells, which differ in CD133 expression: Type 1 (CD133-negative cells able to 
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generate CD133-positive and CD133-negative progeny), Type 2 (CD133-positive cells able to 
generate CD133-negative and CD133-positve cells) and Type 3 (CD133-negative which generate 




Figure 9. GBM cells classified into three clonogenic neurosphere cell types that produce different 
patterns of cells. All cell types can generate grafts in nude mice, but each cell type has distinct growth 
kinetics, histological features, and molecular signatures. Grafts of type I cells generate aggressive and faster-
growing tumors, compared to type III cells that generate slow-growing and circumscribed lesion. 
Furthermore, type II cells form grafts with intermediate features between type I and III. Type I and II cells 
express radial glial markers, including FABP or BLBP and other neural stem cell markers such as nestin and 
GLAST at a much higher level than in type III cells. Indeed, type III cell cultures expressed markers of 
intermediate progenitor cells, including TBR2, DLX2, DLX1 and CUTL2. 
 
 
All these cell type are capable of self-renewal, initiation of neurosphere growth and generation of 
highly malignant tumors. However these cell types have distinct growth kinetics and form tumors 
with distinct histological features, and molecular signatures. 
A hierarchical lineage has been established between these three types of cells, suggesting that type 
I (CD133-negative) cells are the most primordial, whereas type III cells represent the most 
differentiated state, and type II clones are intermediate between the type I and III cells. 
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2. MATERIALS AND METHODS 
 
2.1 Preparation of cell suspensions from patient tumors 
This study was approved by the Ethical Committee for human experimentation of IEO (European 
Institute of Oncology) and all patients signed an approved consent document prior to surgery. 
Surgical specimens of tumors were collected at the Neurosurgery Dpt. at IRCCS Istituto Clinico 
Humanitas and examined by a neuropathologist to verify that each case met criteria for GBM and 
to select a tissue fragment with high content of viable tumor tissue. Each tissue specimen was 
minced in to small pieces and maintained in sterile saline at room temperature. One piece of the 
mincate was fixed in formaldehyde solution (38%) and successively paraffin-embedded; the 
remaining tissue was dissociated into single cell suspension in warmed EBSS (Earle’s Balanced 
Salt Solution) containing papain (2 mg/ml) (Worthington Biochemical), EDTA (0.8 mg/ml) and L-
Cystein (0.8 mg/ml) at 37C for 1-2 hours. The dissociated tumor was filtered through a 70 micron 
filter and washed a minimum of three times prior to culturing or FACS analyses. 
 
2.2 Neurosphere culture 
Neurosphere cultures were maintained in neurosphere culture medium consisting of DMEM-F12 
1:1 (Dulbecco’s Modified Eagle Medium – Ham’s F12 Nutrient Mixture) medium (Invitrogen) 
supplemented with B27 Supplement (Invitrogen), EGF (20 ng/ml), b-FGF (10 ng/ml) (PeproTech) 
and 2 ug/ml Heparin (Sigma), at 37°C in a 5% CO2 humidified incubator. All cultures were 
passaged by mechanically dissociation when spheres reached approximately 300-500 microns in 
diameter, and cell counts were performed at the time of passage. For cultures passaged at intervals 
longer than one week, media containing fresh growth factors was added twice weekly.  
To established neurosphere cultures, dissociated tumor cells were seeded at an initial density of 1-2 
x 105 cells/ml. Sorted populations from each tumor case were matched for plating density. 
 
2.3 Cytotoxic Ab-mediated assay 
The cytotoxicity of anti-CD133 monoclonal antibodies (mAbs) was measured as follows: 3.000 
cells/well were plated in 96-well plates in a volume of 100 µl of complete medium. Twenty-four 
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hours later, the unconjugated mAb directed against epitope 1 of CD133 (AC133 Miltenyi) and the 
Ab directed against HA (Sigma) as control were added at different concentrations. Seventy-two 
hours later, the Ab-containing medium was removed, and the cytotoxic effect of anti-CD133 Ab 
was determined using the MTS/PMS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)- 
2/phenazine methosulfate) microtiter plate assay (Promega). 
 
2.4 FACS analysis and sorting 
CD133 expression was monitored by use of CD133/1 Ab-PE (Miltenyi,). For FACS analysis, all 
patient samples were analyzed within 24 hr of surgery and all cultures were analyzed at 6 days (±1 
day) after passaging. For staining of neurospheres, cultured cells were mechanically dissociated, 
washed with PBS and suspended in cold FACS buffer (PBS with 0.5% BSA and 2mM EDTA) at a 
density of 2x106 cells/ml. For CD133 extracellular staining, CD133/1 Ab-PE (mouse 1:10) was 
added to the cells; for each sample analyzed, a duplicate sample was stained with mouse Ig2a-PE 
(Miltenyi) as an isotype control. Following incubation at 4oC in the dark for 10 minutes, cells were 
washed twice in FACS buffer and fixed in paraformaldehyde 20 minutes on ice. For CD133 
intracellular staining, 106 cells were pre-incubated with a five-fold excess of biotin-conjugated 
CD133/1 Ab to saturate extracellular binding sites. Cells were then permeabilized for intracellular 
staining with the Inside Stain Kit (Miltenyi) for 20 minutes at room temperature, washed once in 
FACS buffer and stained with CD133/1 Ab-PE resuspended in Inside Perm buffer for 10 minutes at 
room temperature. Finally the cells were washed once in Inside Perm buffer and resuspended in 
FACS buffer. Gating for single cells was established using forward scatter in the isotype control 
sample. The isotype control sample was utilized to establish a gate in the PE channel. Cells 
showing signal for CD133 above the gate established by the isotype control were deemed to be 
CD133-positve cells. 
Analysis of patient samples was performed using the CD133/1 Ab-PE. Gating for single viable 
cells was established using forward scatter, side scatter and DAPI staining in the isotype control 
sample. The isotype control sample was utilized to establish a gate in the PE channel. Cells 




For FACS sorting, cells were dissociated into single-cell suspensions and labeled with anti-CD133-
PE Ab (Miltenyi). These labeled cells were then physically sorted using the FACS Vantage SE 
flow cytometer (BD). For magnetic cell sorting, single-cell suspensions were incubated with 
CD133 microbeads and FcR-blocking reagent (Miltenyi), and then separated by using MACS 
separation system (Miltenyi). We have followed the manufacturer's protocol in these steps. In order 
to ensure high purity of sorted populations, we have used two separation columns consecutively. 
We confirmed the purity of cells by FACS analysis of tumor cells after cytofluorimetric or 
magnetic sorting. Purities of sorted CD133-positive and CD133-negative cells from a series of 
freshly dissociated tumors or neurosphere lines were determined to be about 95.8% and 97.2%, 
respectively. 
 
2.5 Lentiviral mediated CD133 silencing 
The vector pLentiLox3.7-Puro-GFP (pll) was used to generate lentiviral plasmids that express short 
hairpin RNAs (shRNAs) based on the cDNA of CD133; sh1 corresponds to nucleotides 949–967 
(exon 7) (GACCCAACATCATCCCTGT) (Rappa et al, 2008), sh2 corresponds to nucleotides 885-
905 exon 6 (AAGGCGTTCACAGATCTGAAC); Genbank accession no. NM006017. BLAST 
research ensured that the sequences have no significant homology with other human genes. As 
control vectors, we used the same lentiviral vector carrying a shRNA sequence nonspecific to any 
human gene (CGTACGCGGAATACTTCGA). 
Sequences encoding short hairpin RNAs were cloned into the XhoI and HpaI sites of a modified 
pLentilox 3.7 vector, in which the NheI/EcoRI fragment encoding GFP was replaced by a 
NheI/EcoRI fragment containing the PUROMYCIN resistance gene fused to GFP sequence. 
To generate lentiviral particles, pll-sh1, pll-sh2 and pll-NT as control were transfected into 293T 
packaging cell line together with the packaging plasmids pMDLg/pRRE, pRSV-REV and pMD2G 
by calcium phosphate transfection method. Viral particle-containing supernatants were collected at 
48 hours after transfection and filtered through 45 microns filter. One volume of PEG-it Virus 
Precipitation Solution (System Bioscience SBI) was added to every four volumes of lentiviral 
supernatant. The supernatant/PEG-it mixture was incubated at least for 12 hours at +4oC and 
centrifuged at 1500xg for 30 minutes. The lentiviral pellet was resuspended in PBS and stored at -
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80°C. Viral titer was measured by serial dilution of virus on 293T cells followed by FACS analysis 
of GFP-positive cells 48h after infection.  
For infection, 5 x 107 viral particles were added to 105 cells in the presence of 8 µg/mL polybrene 
(Sigma-Aldrich). Three days after infection, cells were selected in puromycin (Sigma-Aldrich) for 
three days and then used for experiments.  
 
2.6 Western blotting 
Cells were lysed in ice-cold lysis buffer (50 mM Tris-Cl pH8, 150 mM NaCl, 5 mM EGTA pH8, 
1,5 mM MgCl2, 10% glycerol, 1% Triton, 50 nM NaF, 10 mM NaPP, 10 mM NaVO4, 10 mM 
PMSF, 10 µM leupeptin and 10 µM aprotinin) for 15 minutes on ice. Lysates were centrifuged at 
12000 rpm, supernatant collected and protein concentration was measured by the Bradford assay 
(Biorad). Equal amounts of total proteins were loaded onto 1.5 mm thick polyacrylamide gels for 
electrophoresis. The proteins were transferred in western transfer tanks (Biorad) to nitrocellulose in 
1x transfer buffer (20% methanol). Filters were blocked in 5% milk in TBS (125 mM NaCl, 25 
mM Tris pH8, 0,1% Tween) for 1 hour at room temperature. Primary antibodies and dilutions used 
were: CD133/1 (W6B3C1, mouse monoclonal, Miltenyi, 1:100) and actin (mouse monoclonal, 
Sigma-Aldrich, 1:1000) used to normalize the amount of lysate loaded on the gel. The bound 
primary antibody was detected with horseradish peroxidase-conjugated (HRP) secondary antibody 
(Sigma-Aldrich) using ECL (Enhanced ChemioLuminescence) Western Blotting detection reagent 
(Amersham Bioscences). 
 
2.7 Quantitative RT-PCR analysis 
Total RNA from neurosphere cultures was isolated with RNeasy Mini kit (Quiagen), while total 
RNA from FFPE paraffin embedded brain slides was isolated with FFPE RNeasy FFPE kit 
(Quiagen). Polymerase chain reaction with reverse transcription (RT–PCR) was performed using 
the M-MuLV reverse transcriptase (Finnzymes). Quantitative PCR (qRT-PCR) was performed 
using the Syber Green PCR Master Mix (Applied Biosystems) and signals were detected using a 
7,500 Fast Real-Time PCR System (Applied Biosystems). Data were analyzed with the AB 
Sequence Detection Software, Version 1.4 (Applied Biosystems) using TBP in neurospheres and 
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HPRT1 in xenotrasplanted mouse brains, amplified with human specific primers, as housekeeping 
genes. All samples were run in triplicate in each experiment and results were expressed as mean + 
standard deviation. Q-PCR primer sequences used: 
CD133    forward   5’ - ACCAGGTAAGAACCCGGATCAA - 3’ 
               reverse   5’ - CAAGAATTCCGCCTCCTAGCACT - 3’  
ACTIN    forward   5’ - AGAAAATCTGGCACCACACC - 3’ 
               reverse   5’ - AGAGGCGTACAGGGATAGCA - 3’  
HPRT1   forward   5’ - TGACCTTGATTTATTTTGCATACC - 3’ 
               reverse   5’ - CGAGCAAGACGTTCAGTCCT - 3’ 
 
2.8 Clonogenic assay 
The colony forming cell assay, or methylcellulose assay,  is based on the ability of progenitor cells 
to proliferate and differentiate into colonies in a semi-solid media, in response to growth factors 
stimulation. The colonies formed can be enumerated and characterized according to their unique 
morphology. 
The standard protocol was used with minor modifications. The cells were resuspended in D-
MEM/F12 medium with growth factors and an equal volume of Methylcellulose (StemCell 
Technologies) was added; the methylcellulose concentration in the final cell mixture was 
approximately 1.27%. 1.5 mL (3000 cells) of the final cell mixture was added to a 35 mm culture 
plate with grid (at least three plates were prepared for each condition). The medium was spread 
evenly by gently rotating the plate. Three sample plates and an uncovered plate containing 3 - 4 mL 
sterile water, necessary to maintain the humidity necessary for colony development, were placed in 
a 100 mm culture plate and covered.  
The cells were incubated for 14 - 16 days at 37° C and 5% CO2, avoiding disturbing the plate 
during the incubation period to prevent shifting of the colonies. The colonies were scored at the end 
of the incubation period. Individual colonies were identified and counted using an inverted 





2.9 Analysis of apoptosis 
For apoptosis analysis, infected cells (GFP+) were first fixed in 1% formaldehyde for 20 minutes 
on ice, washed once in PBS and fixed again in ethanol 75% for 30 minutes on ice. Fixed cells were 
incubated in Propidium Iodide (2.5 µg/ml) and RNAse (250 µg/ml) for 12 - 16 hours at +4oC and 
analyzed by flow cytometry. 
 
2.10 Animal experiments 
An intracranial orthotopic model was utilized for evaluation of cell tumorigenicity. Cells from 
dissociated neurospheres were resuspended in 2 µl of PBS and stereotaxically injected into the 
nucleus caudatus (coordinates: 0.7 - 1 mm posterior, 3 mm left lateral, 3.5 mm in depth from the 
dura) of 5-weeks-old female CD-1 nude mice. The mice were maintained until development of 
neurologic signs and then killed for the analysis of tumor histology and immunohistochemistry. 
CD-1 nu/nu mice were housed in plastic cages and were kept in a regulated environment (22 ± 1°C; 
55 ± 5% humidity), with a 12 h light/dark cycle (lights on at 7:00 A.M.). Food and water were 
available ad libitum.  
T2-weighted MR images were obtained using a 9.4-T magnet (Varian) and tumor areas were 
calculated from resulting images on a single scan in 3 mice per group using ImageJ software.  
Experiments involving animals were performed in accordance with the Italian Laws (D.L.vo 
116/92 and following additions), which enforces EU 86/609 Directive (Council Directive 
86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative 
provisions of the Member States regarding the protection of animals used for experimental and 
other scientific purposes).  
 
2.11 Immunohistochemistry and immunofluorescence 
For Hematoxylin and Eosin staining, sections were deparaffinized in xylene, rehydrated in a graded 
alcohol series and stained in Mayer hematoxylin. After counterstain in eosin-phloxine B solution 
the sections were dehydrated in alcohol and cleared in xylene. For immunohistochemistry, mouse 
brains and human surgical samples were formalin fixed and paraffin-embedded. 5 µm sections 
were cut and placed onto Polysine slides (Thermo Scientific), deparaffinized with xylene and 
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rehydrated in a graded alcohol series. Tissue endogenous peroxidases were blocked with 3% 
hydrogen peroxide and antigen retrieval was carried out in EDTA (0.01 M, 0.05% Tween pH6) or 
sodium citrate (0.01 M, pH 6.0) in a waterbath (at 98 °C for 40 min). Paraffin embedded sections 
were blocked with 5% goat serum in PBS for 60 minutes, and incubated overnight with primary 
antibodies: GFP (mouse monoclonal, SantaCruz, 1:200), CD133 (AC133 clone mouse monoclonal, 
Miltenyi, 1:100). Tissue sections were washed in PBS and incubated with a secondary biotinylated 
antibody (Vector Lab, 1:200) for 1 hour. Antibody binding was detected using a Vectastain Elite 
Avidin-Biotin-Complex-Peroxidase kit following manufacturer’s instructions. All sections were 
counterstained with Mayer’s haematoxylin and visualized using a bright field microscope. 
Immunofluorescence staining of neurosphere cells was carried out by fixing cells with 4% 
paraformaldehyde (PFA) for 10 minutes and then permeabilized with 0.2% saponin  in blocking 
buffer (PBS containing 2% foetal calf serum; FCS). Cells were sequentially incubated for 1 hour 
with CD133 antibody (W6B3C1 mouse monoclonal, Miltenyi, 1:100), Ki67 (mouse monoclonal, 
BD Pharmingen, 1:50), Cleaved Caspase-3 (rabbit polyclonal, Cell Signaling, 1:100) at room 
temperature followed by 1 hour incubation with Cy3-conjugated AffiniPure donkey-α-mouse IgG 
(H+L) Fab fragment (Jackson ImmunoResearch Laboratories) at room temperature. 
In the case of cell surface versus intracellular labeling, cells were first cell surface labeled with 
mAb CD133/1 (W6B3C1 clone) diluted in blocking buffer for 30 minutes in the cold, followed by 
30 minutes incubation with Cy3-conjugated AffiniPure donkey-α-mouse IgG (H+L) Fab fragment 
(Jackson ImmunoResearch Laboratories) at +4oC. Then the cells were fixed in Inside Fix Buffer 
(Miltenyi) 30 minutes RT and quenched with 0.1 mM glycine. Remaining mouse epitopes were 
saturated by incubation with unconjugated AffiniPure rabbit- α-mouse IgG (H+L) Fab fragment 
(Jackson ImmunoResearch). Afterward, cells were post-fixed with 0.2% PFA, permeabilized with 
Inside Perm Buffer (Miltenyi) and finally labeled with mAb CD133 for 30 minutes RT, followed 
by 30 minutes incubation with FITC-conjugated sheep-α-mouse IgG (H+L) Fab fragment (Sigma).  
As controls, no signal was observed when anti-CD133 primary antibody was omitted or only the 
CD133 immunoreactivity was detected when the second primary antibody was omitted, indicating 
that the first mouse primary antibody was fully saturated. 
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In all cases, nuclei were labeled with DAPI (Molecular Probes). The cells were mounted in 
glycerol. Confocal analysis was performed using Leica TCS SP2 microscope driven by Leica 
software. A 63x oil immersion objective (NA 1.4) was used. The same optical section thickness 
was set for all channels. Individual sections (0.5/1.0 µm interval) and their lateral projections are 
shown. The images shown were prepared from the confocal data files using ImageJ free software 
(rsbweb.nih.gov/ij/).  
 
2.12 Microarray Analysis 
Neurospheres derived from four different patients with different expression levels of CD133 were 
infected with NT and sh2 shRNAs and collected 72 hours after infection. Total RNA was isolated 
using with RNeasy Mini kit (Quiagen). Quantity and quality of total RNA samples was 
determinated using ND-8000 spectrophotometer (Nanodrop Technologies) and Agilent's 
Bioanalyzer 2100 (Agilent Technologies), respectively. The gene profile analysis was performed 
using the Affymetrix Microarray technology, available at Cogentech, within the IFOM-IEO-
Campus.  
Gene expression data were generated using Affymetrix exon expression chips HuGene-1_0-st-v1. 
Cel files were loaded into Genespring 11.0 software and expression values were obtained using 
RMA16 as summarization algorithm in conjunction with the core algorithm for transcript level 
selection. Each shCD133-treated sample was normalized to its NT-vector treated counterpart and 
ANOVA (P<=0.05) was performed to identify significant changes in shCD133-treated samples. 
Alternatively, genes were filtered on fold change with cutoffs varying between 1.2 and 1.5. The 
resulting gene lists were analyzed using Ingenuity Pathway Analysis software to identify 
significant overlaps with canonical pathways. 
 
2.13 Statistical Analysis 
Statistical analyses were performed using Prism 5.0 software. Data graphed with error bars 
represent mean + standard deviation. Two-tailed Student’s t test or one-way analysis of variance 
(ANOVA), corrected for multiple comparisons as appropriate, were used to determine the 
significance of any differences between experimental groups. In Kaplan Meyer curves, the 
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survivals were compared with log-rank analysis. Differences were considered “statistically 




3. STUDY OBJECTIVES 
 
Several evidences have been reported about the existence of cells with stem-like properties in 
human glioblastoma. These cells have been identified on the basis of the expression of the cell 
surface marker CD133 and showed self-renewal potential and the capacity to recapitulate the 
human tumor characteristics when transplanted into the brain of immunodeficient mice. On the 
other hand, CD133 have been proved not to be an informative marker in some human GBM cases 
for several reasons: 
- CD133 expression is variable in glioblastomas (1% - 60%); 
- GBMs with undetectable levels of CD133 exist. Neurospheres have been isolated from these 
tumors and they have tumorigenic potential in vivo (Beier et al, 2007; Son et al, 2009); 
- CD133- negative cells isolated from CD133 expressing neurospheres are tumorigenic in nude rats 
(Wang et al, 2008) and nude mice (Joo et al, 2008). 
Considering the aforementioned notions a definitive conclusion about the usefulness of CD133 as 
glioblastoma stem cell marker is difficult to drawn.  
Moreover very little is known about the structure and the biological functions of this protein. 
The aims of this study are mainly: 
1) to study the role of CD133 in the identification of cancer stem cells derived from human 
glioblastomas and their derived neurospheres. Using the FACS sorting, the CD133-positive and 
CD133-negative cell fractions were compared for the self-renewal capacity in vitro, measured with 
the methylcellulose assay, and for their tumorigenic potential, transplanting the cells into the brain 
of nude mice; 
2) to study the biological function of CD133 in glioblastoma stem cells. CD133 was knocked-down 
in GBM derived neurospheres, isolated from different patients, using lentivirus mediated shRNAs. 
The stem-like properties were analyzed in the CD133-silenced cells using the in vitro clonogenic 





4.1. CD133 is variably expressed in human glioblastomas and their derivative 
neurospheres. 
We examined a series of newly diagnosed and recurrent glioblastoma cases, classified as grade IV 
according to the WHO system, to investigate the expression level of CD133 in acutely dissociated 
tumors and in established neurospheres cultures. 
We screened for the plasma-membrane expression of the stem cell-associated epitope AC133 
(CD133/1), widely used to identify and isolate stem cells from brain tumors (Singh et al, 2004). 
However, its nature and specific characteristics are still not clear: multiple results show that it was 
generated by post-translational modifications (like glycosylation) (Bidlingmaier et al, 2008) or 
specific folding of the protein, lost upon stem cell differentiation (Kemper et al, 2010). 
We have established neurosphere cultures from GBM patient specimens by culturing freshly 
dissociated cells in serum-free media in the presence of FGF and EGF; these conditions are 
commonly used to culture neural stem cells (Lee et al, 2006). In order to be defined as cancer 
stem/progenitor cell populations, these cells are required to be clonogenic in vitro, express stem 
cell markers (like Olig2 or Sox2) (Ligon et al, 2007; Yuan et al, 1995), be capable of neuronal 
and/or glial differentiation and be tumorigenic in vivo, generating xenograft tumors that 





Figure 10.  Representative images of Hematoxylin and Eosin staining of parental and xeno- tumors. 





Name Survival time 
GBM#7 53.3 ± 6.15 
GBM#8 87.3 ± 8.3 
GBM#9 92.33 ± 10.6 
GBM#10 110 ± 3.05 
GBM#11 76.3 ± 15.5 
GBM#18 67.8 ± 4.9 
GBM#20 70.8 ± 5.8 
GBM#21 65.1 ± 2.5 
GBM#23 135.6 ± 29.19 
GBM#24 96.3 ± 5.1 
GBM#25 142.5 ± 0.7 
	  
	  
Table 1 Tumorigenic capacity of GBM-derived neurosphere cells. GBM-derived neurospheres were 
dissociated into single cells and 105 cells were injected into the brain of immunocompromised mice. Animals 
were monitored since neurological signs became evident and then sacrified. The presence of tumors was 
analyzed by Haematoxilin and Eosin staining on FFPE brain slides. Average ± standard deviation of the 
survival time (in days) of xeno-transplanted mice is reported.  
	  
	  
We determined the expression of CD133 in different GBM-derived neurospheres by fluorescence 
activated cell sorting (FACS) analysis. Our screening revealed that the neurospheres analyzed had a 




Figure 11. Representative FACS plots of extracellular CD133 expression in neurosphere lines. GBM#9 
(with an abundance of CD133+ cells), GBM#10 (with an intermediate number of CD133+ cells) and 
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GBM#18 (with a paucity of CD133+ cells) neurospheres were dissociated and analyzed by FACS for the 
CD133 expression.     In cells stained with the antibody against CD133 (right panels), CD133+ and CD133- 




Four of 11 neurosphere lines included in the study had an abundance of CD133-positive cells (from 
84.8%- to 58.1%), (called CD133-high cells), similar to what has been previously reported 
(Piccirillo et al, 2006; Singh et al, 2004). The other seven neurospheres contained smaller 
populations of CD133-positive cells (called CD133-low cells) ranged from 8.4% to 1.0%. No 
GBM-derived neurospheres with undetectable levels of CD133 expression were found, in contrast 


















Neurospheres GBM#7 Recurrent 3.7 p6 2.8±1.0 p8-15 
 GBM#8 Newly Diagnosed 4.4 p6 3.1±0.9 p9-14 
 GBM#9 Recurrent 81.3 p2 78.7±17.3 p5-13 
 GBM#10 Recurrent 58 p3 47.1±6.4 p6-13 
 GBM#11 Newly Diagnosed 84.8 p2 ND ND 
 GBM#18 Recurrent 6.8 p2 6.3±2.2 p4-10 
 GBM#20 Newly Diagnosed 2.4 p2 4.6±2.2 p4-8 
 GBM#21 Newly Diagnosed 1.0 p2 4.1±4.1 p3-7 
 GBM#23 Newly Diagnosed 53.1 p3 34.9±12.5 p6-14 
 GBM#24 Newly Diagnosed 4.36 p6 ND ND 
 GBM#25 Newly Diagnosed 8.4 p2 9.3±1.2 p4-6 
GBM#26 Newly Diagnosed 0.27 p0 ND ND 
GBM#29 Newly Diagnosed 0.6 p0 ND ND 
Freshly 
isolated tumor 
cells GBM#30 Newly Diagnosed 0.37 p0 ND ND 
 GBM#31 Newly Diagnosed 8.0 p0 ND ND 
 GBM#33 Recurrent 3.6 p0 ND ND 
 GBM#34 Recurrent 13.9 p0 ND ND 
 
Table 2. CD133 expression in GBM-derived neurospheres and in freshly dissociated tumors. Percentage 
of CD133+ cells (detected with the CD133/1 antibody) in dissociated neurospheres and in freshly isolated 
tumor cells was analyzed by FACS at two different in vitro passages. CD133-high cells are in red, CD133-




We have also studied CD133 expression in acutely dissociated tumors. Using flow cytometry, we 
found that 3 out of 6 tumors had less than 1% of CD133-positive cells, while the other 3 cases 
53	  
	  
displayed higher CD133 positivity, ranging from 3.6% to 13.9% positive cells (Figure 12 and Table 




Figure 12. FACS plots of extracellular CD133 expression in freshly isolated surgical biopsies. Patient 
GBM#30, with a paucity of CD133+ cells, and patient GBM#34, with more CD133+ cells, are represented. 
In not PFA fixed samples DAPI is used to identify not viable cells. In the left plots (A) DAPI signal (y-axis) 
is plotted against the forward scatter (FSC) (x-axis). In cells stained with DAPI (left panels), the DAPI+ and 
DAPI – cells are identified in a FACS gate (black line) established in corresponding unstained plots. In the 
right panels CD133/1-PEsignal (y-axis) is plotted against the forward scatter (FSC) (x-axis). In DAPI 
negative cells (viable cells) stained with antibody to CD133 (right panels), CD133+ and CD133- cells are 
identified by a FACS gate (black line) established in corresponding isotype control plots. 
 
 
No significant differences in the capacity to grow as neurospheres and in the tumorigenic potential 
were observed between CD133-high and CD133-low neurospheres, although different 
neurospheres varied in the frequency of clonogenic cells. 
Analysis of the different neurosphere lines revealed substantial variation in the percentage of 
CD133-positive cells that remained constant for individual cell line over several in vitro passages 
(Table 2). 
In order to determine whether these CD133-positive cells identified in the neurospheres exist in the 
corresponding human GBMs in situ, we performed immunohistochemical analysis of patient-
derived GBM paraffin sections. A subpopulation of cells with distinct cell membrane-associated 
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CD133 was detected in GBM patients, revealing the consistency between in vitro data and 
qualitative immunohistochemical evaluation (Figure 13). Interestingly, we noticed a cytoplasmic 
localization of CD133 rather than exclusive plasma membrane associated expression, in accordance 
to previous results (Campos et al, 2011; Ferrandina et al, 2009; Immervoll et al, 2008; Sasaki et al, 
2010). In some cases, such as GBM#20, the neurospheres contained few CD133-positive cells 
while the corresponding tumor sample presented high CD133 expression, with a clear cytoplasmic 
localization. This result suggested an exclusive cytoplasmic localization of CD133 in some cases, 





Figure 13. Immunohistochemical staining of CD133. Representative human GBM specimens: the 
corresponding neurospheres have been found by FACS to contain either high (GBM#9) or low (GBM#21 
and GBM#20) percentages of CD133+ cells. In some cases the expression pattern of CD133 in the 
neurospheres and in the corresponding tumor are comparable; in others CD133 is expressed at higher levels 
in the tumor compared to the derived neurospheres. In all cases the localization of the protein is clearly 
cytoplasmic. Scale bar, 50 µm; in boxed areas CD133+ cells at higher magnification are represented.   
 
 
4.2. Cytoplasmic localization of CD133 in GBM-derived neurospheres 
In an attempt to further characterize the GBM-derived neurospheres for the expression of CD133, 
we analyzed CD133 mRNA expression levels by qRT-PCR. We found that in the majority of the 
samples analyzed, CD133 mRNA expression levels were consistent with the percentages of 
CD133+ cells measured by FACS: CD133-high neurospheres showed the highest CD133 mRNA 
levels. However, in 5 out of 7 CD133-low cells, CD133 transcript levels were only slightly lower 
than those of CD133-high cells (Figure 14) suggesting that mRNA levels not always reflect the 
CD133 levels in the membrane.  The heterogeneous expression of CD133 mRNA in the 
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Figure 14. CD133 mRNA expression in GBM-derived neurospheres. Total RNA extracted from cultured 
neurospheres was analyzed for CD133 expression using qRT-PCR. TBP is used as reference gene for 
normalization of CD133 expression levels. The CD133 expression levels varied higly among different 




Analysis of total cell lysates showed comparable expression levels of CD133 in some CD133–low 




Figure 15. Expression of CD133 in CD133-low GBM-derived neurospheres analyzed by Western 
blotting. 30 micrograms of total cell lysate were loaded on an 8% polyacrylamide gel. 5 micrograms of total 
cell lysate of GBM#9 were used as positive control. To identify a potential negative cell line to use as 
negative control, we analyzed several cell lines by qRT-PCR and Western blotting. To our surprise, we found 
all cell lines to be positive for CD133 (Shmelkov et al, 2004). We than decided to use the Hela cell line that 






We investigated the CD133 localization within the neurosphere cells by immunofluorescence 
microscopy. The cell surface labeling revealed that CD133 is uniformly distributed in the 
plasmamembrane (Figure 16, red). Remarkably, a second labeling performed upon cell 
permeabilization revealed an additional, intracellular staining of CD133 (Figure 16, green). Thus, 
two distinct pools of CD133 molecules co-exist in GBM-derived neurosphere cells. Of note, the 
majority of cells showed both an extra- and intra-cellular localization CD133 in GBM#9 and 
GBM#10 neurospheres, while CD133 had an exclusive intracellular localization in GBM#18 cells. 




Figure 16. Two pools of CD133 co-exist in GBM-derived neurosphere cells.  
GBM-derived neurosphere cells were first cell surface-labeled for CD133 (red) prior to PFA fixation and 
saponin permeabilization followed by a second round of CD133 labeling (green). The nuclei were stained 
with DAPI (blue). The labeled cells were analyzed using confocal laser scanning microscopy. A single 
optical x-y-plane section is shown. Scale bar, 10 µm 
  
 
In addition, we performed a flow cytometry analysis of intracellular CD133 and we found a 
cytoplasmic localization of CD133 in almost all the neurospheres analyzed; in particular the 
CD133-low neurospheres had a discrete amount of intracellular CD133 (Figure 17). Notably, not 
all CD133-low cells had cytoplasmic expression of CD133, suggesting that a population of cells 








Figure 17. Flow cytometry analysis of extracellular and intracellular CD133 protein expression. CD133 
expression on the cell surface or in the cytoplasm was analyzed in CD133-high and CD1333-low 
neurospheres using FACS analysis. Graphs show mean values and corresponding standard deviation of 
percentage of CD133+ cells calculated in two independent experiments. (C) Representative dot plots showing 
a flow cytometry analysis of extracellular and intracellular CD133 protein expression and a corresponding 
isotype control for the GBM#9 neurospheres. CD133/1-PE signal (y axis) is plotted against the forward 
scatter (FSC) (x axis). 
 
 
4.3. Characterization of CD133-positive and CD133-negative cells 
4.3.1 CD133 is localized in cytoplasm of CD133-negative cell fraction 
The previous results suggested us the existence of at least two populations of cells within the 
neurosphere: 1. CD133 plasma-membrane associated cells, 2. CD133 cytoplasmic localized cells 
(with or without CD133 on the plasma-membrane). In order to further investigate in the phenotype 
of GBM-derived cells with respect to CD133 expression and sub-cellular localization, we sorted 
the cells into CD133-positive and CD133-negative fractions. We analyzed the sub-cellular 
localization and the expression levels of CD133 protein and mRNA in the two cell fractions. Then 
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we moved to analyze the capacity of these fractions to initiate neurosphere growth, the cloning 
efficiency and the tumorigenic potential. 
We used fluorescence activated cell sorting (FACS) and magnetic beads separation to sort CD133-




Figure 18. Sorting of GBM-derived neurospheres using CD133. (A) Scheme of the method. (B) 
Representative examples of sorting windows of GBM-derived neurospheres. For each FACS plot, a gate 
(black box) established on the base of the isotype control plot (left panels) separates cells quantified as 




Surprisingly the CD133-positive and CD133-negative cell fractions showed comparable expression 
levels of CD133 protein and mRNA when total cell lysates were analyzed by Western blotting and 
qRT-PCR (Figure 19 A and B). The total CD133 expression levels didn’t change after culturing the 




Figure 19. Analysis of CD133 expression in cell fractions sorted on the bases of CD133 cell surface 
expression. Total lysates of unsorted (US), CD133+ and CD133- cells were collected immediately after 
sorting (post sorting), and after 15 days of in vitro culture in methylcellulose (DIV days in vitro). The overall 
levels of CD133 expression do not vary in the three cell fractions.  (A) Western blotting with AC133 mAb. 
10 micrograms of total cell lysate were loaded on a 10% polyacrylamide gel. 2 micrograms total cell lysate of 
Caco2 are used as positive control. 10 micrograms of Hela total cell lysate are used as negative control. Actin 
is used as loading control. (B) CD133 mRNA expression is assessed by qRT-PCR. TBP is used as reference 
gene for normalization of CD133 expression levels. Bars show mean values and corresponding standard error 
of three independent experiments. 
 
 
These findings induced us to look at the sub-cellular distribution of CD133 in the sorted CD133-
positive and CD133-negative cell fractions. As expected we found that CD133 was not expressed 
on the plasma-membrane in almost all CD133-negative cells, however it was exclusively diffused 
in the cell cytoplasm (Figure 20). This observation is in accordance with other recent studies that 
reported a cytoplasmic localization of CD133 in tumor cells. After 15 days in culture, the CD133-
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positive and CD133-negative cells had the same sub-cellular distribution of CD133, with the 




Figure 20. Subcellular localization of CD133 in CD133+ and CD133- sorted cell fractions. Neurosphere 
cells sorted for CD133 were first cell surface-labeled for CD133 (red) prior PFA fixation and saponin 
permeabilization, followed by a second round of CD133 labeling (green). CD133 is localized on the cell 
surface (not permeabilized cells) and in the cytoplasm of CD133-positive, while is localized exclusively in 
the cytoplasm of CD133-negative cells, when labeled immediately after sorting. After 15 DIV (days of in 
vitro) the two cell fractions have the same sub-cellular distribution of CD133. The nuclei were stained with 
DAPI (blue). The labeled cells were analyzed using confocal laser scanning microscopy. A single optical x-
y-plane section is shown. Scale bar, 10 µm 
 
 
Flow cytometry analysis of intracellular CD133 in GBM#10 and GBM#23 neurospheres showed 
cytoplasmic expression of CD133 in the unsorted, CD133-positive and CD133-negative cells 
(Figure 21). Moreover, almost all CD133-membrane positive cells have intracellular CD133, while 
only the 40% and 25% of CD133-membrane negative cells of GBM#10 and GBM#23 respectively 
were positive to the intracellular staining (Figure 21). This result suggests that a discrete amount of 
cells not expressing any CD133 composes the neurosphere. Of note, after 15 days in culture the 
three cell fractions had similar extracellular and intracellular CD133 localization (Figure 21). This 
is a strong indication of a dynamic plasma-membrane localization of CD133 in the cell, probably 
subjected to a re-cycling from the plasma-membrane to cytoplasm and viceversa. Nevertheless the 
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possible existence of a hierarchical organization between the CD133-positive and CD133-negative 




Figure 21. Extracellular and intracellular staining of CD133. Extracellular (black) and intracellular (grey) 
CD133 expression were analyzed in unsorted (US), CD133+ and CD133- cell fractions (GBM#10 and 
GBM#23) using FACS, immediately after sorting (post sorting) and after 15 days in culture (DIV days in 
vitro). Bars show mean values and corresponding standard deviation of two independent experiments 
 
 
4.3.2 CD133-membrane negative cells have reduced clonogenic capacity 
The CD133-positive and CD133-negative cell fractions sorted from GBM#10 and GBM#23 
neurospheres displayed qualitative similar results for neurosphere growth in the sense that both 
fractions generated expandable neurospheres, although CD133-negative cells formed spheres 
slightly smaller in size than the CD133-positive cells (Figure 22 A). 
The clonogenic efficiency was analyzed seeding the cells at low density in methylcellulose whose 
viscous composition does not allow the cells to aggregate. Single clones were counted after 15 days 
and the clonogenic cells were calculated as percent on the total seeded cells. The two GBM-derived 
neurosphere lines varied in their frequency of clonogenic cells: in both cases was observed a 
difference in the clonogenicity of CD133-positive and CD133-negative cells (Figure 22 B) and in 
the appearance of the neurospheres derived from them. However, CD133-positive cells formed 
more and larger colonies in methylcellulose than the CD133-negative cells (Figure 22 A), 
suggesting an increased self-renewal capacity. Interestingly, when the spheres formed in 
methylcellulose were dissociated and re-plated in the same conditions, there was no difference in 
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clonogenic capacity and sphere size between the two cell fractions (Figures 22 A and B).  
Intriguingly, the changes in sub-cellular localization of CD133 could correspond to the acquisition 




Figure 22. Clonogenic capacity of CD133-positive and CD133-negative cells. (A) Representative 
microphotographs of GBM#10 and GBM#23 spheres formed in methylcellulose by unsorted cells and 
CD133+ and CD133- fractions immediately after sorting and after 15 days in culture (DIV days in vitro) 
Scale bar, 200 µm. (B) Quantification of cloning efficiency of unsorted and sorted cells. CD133- cells are 
less clonogenic than CD133+ cells post sorting. After re-plating (at day 15 after sorting) the clonogenic 
capacity becomes equal between CD133+ and CD133- cells. Bars represent means and corresponding 





To further investigate the self-renewal capacity of these cells and to understand if a hierarchy could 
be established between CD133-positive and negative cells, we cloned single cells of each fraction 
and analyzed the plasmamembrane-associated-CD133 expression for each secondary population. 
Every clone examined was found to contain cells that initiate growth of secondary clones similar to 
the initial clone for appearance, growth and CD133 expression (Figure 23). Secondary clones from 
CD133-positive cells invariably contained a mixture of CD133-positive and CD133-negative cells 
and the percentage of CD133-positive cells in these expanded clonal cultures did not differ from 
the unsorted population. In addition all the secondary clones derived from CD133-negative cells 
contained a mixture of CD133-positive and CD133-negative cells, although there was a great 




Figure 23. Clonal analysis of CD133+ and CD133- cells. Percentage of CD133+ cells, analyzed by FACS, 
in secondary clones formed by unsorted, CD133+ and CD133- single cells (GBM#9 and GBM#10) collected 
immediately after sorting. 30 and 10 clones per group were analyzed for GBM#9 and GBM#10 respectively. 
T-tests with Bonferroni’s correction for multiple comparisons reveal no difference among groups. Bars 
represent median values. 
 
 
We were not able to identify clones not re-expressing CD133 on the plasma-membrane or not 
expressing any CD133. These findings are consistent with a dynamic regulation sub-cellular 
localization of CD133 suggesting a shuttle of the protein between cytoplasm and plasma 
membrane, mediated by undetermined stimuli. In addition these results are in contrast with the 
lineage hierarchy model established between CD133-positive and CD133-negative cells by Chen et 





4.3.3 Cytotoxic effect of Anti-CD133 mAb 
Since the clonogenic potential of cells that do not express CD133 on the plasma-membrane is 
reduced, even if only transiently, it seems plausible that the plasma membrane localization of 
CD133 is important for the stem properties of the cell.  
To investigate whether the block of plasma-membrane CD133 results in any effect on the cells, we 
exposed the GBM-derived neurospheres to an anti-CD133 antibody. We treated cells expressing 
different levels of CD133 with different doses of AC133 mAb and measured the percentage of 
viable cells after 72 hours. A dose dependent cytotoxic effect of AC133 mAb on neurosphere cells 
was observed (Figure 24). The growth of cells treated with the anti-HA antibody was not inhibited. 
The cytotoxic effect was observed only at the highest doses tested (5 – 10 µg/ml) in GBM#7 and 
GBM#18 cells, which express lower levels of cell surface CD133. The major effect in GBM#9 and 
GBM#10 cells can be explained by the fact that they express higher levels of cell surface-
associated CD133. These results suggest that the cell surface associated CD133 is essential for the 







Figure 24. Cytotoxic effect of CD133/1 mAb in GBM-derived neurospheres. Cells were plated in 
complete medium and exposed to different concentrations of CD133/1 mAb for 72 hours. Cells treated with 
anti-HA Ab were used as control for cross-reactivity. Cytotoxicity was assessed by an MTS/PMS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2/phenazine methosulfate) assay. SE (standard error) 
bars are presented at each measurement. (*) p≤0.05 and (**) p≤0.01 with one-way ANOVA comparison of 
the control group (anti-HA treated cells) to the corresponding anti-CD133 treated groups on the same day. 
 
 
4.4 Both CD133-positive and CD133-negative cell fractions are tumorigenic in vivo 
We examined the ability of progeny from CD133-positive and CD133-negative cells to generate 
orthotopic tumors in nude mice. For these studies, we inoculated sorted cells (n = 100000 per 
mouse) into the forebrain of 5 weeks old nude mice. Unsorted cells were injected as controls. All 
the three population of cells (unsorted, CD133+ and CD133-) formed tumors in mice, although the 
overall survival of tumor-bearing animals was significantly shorter in CD133-positive cell-injected 






  Tumor incidence Survival Average ± SD (days) 
Unsorted 6/6 105.6 ± 5.7 
CD133+ 6/6 102.1 ± 5.2 
GBM#10 
CD133- 6/6 122.1 ± 5.5 
Unsorted 3/3 113 ± 2 
CD133+ 3/3 107.3 ± 2.6 
GBM#23 
CD133- 4/4 121 ± 4.1 
 
 
Figure 25. Kaplan-Maier survival graphs of mice injected with CD133 sorted cells. The animals were 
injected with unsorted, CD133+, or CD133- cells immediately after sorting. 100000 cells were orthotopically 




A series of mice, each inoculated with GBM#10 neurosphere cells, were monitored by magnetic 
resonance imaging (MRI) 4 weeks after implantation. Although all the mice inoculated with 
unsorted and CD133-positive cells harbored sizeable lesions at this time point, most mice implanted 






Figure 26. Representative T2 MRI images of grafts formed by unsorted, CD133+ and CD133- cells. 
Grafts formed by unsorted and CD133+ cells are visible at 4 weeks after implantation, whereas lesions from 
CD133- cells are typically not apparent or small at 4 weeks. These images are representative of the results 
from a total of 3 mice. Yellow line highlights tumor area. Bars represent the mean value of tumor area and 
standard deviation. (**) p≤ 0.01 calculated with two sided Student’s t test. 
 
 
However, histological analysis of mice, killed when showed neurological defects associated with 
signs of suffering and pain, demonstrated that tumors arose in all mice inoculated with the three cell 
populations (Figure 27 A). The cells showed similar diffuse growth, causing enlargement of the 
brain and hyperemia (in particular the GBM#10-derived cells), and infiltrated in the brain diffusely 
including the corpus callosum and the controlateral hemisphere (in particular the GBM#23-derived 
cells). The tumors were similar in cytoarchitecture, vascularization and invasiveness at the tumor 
center and periphery. Consistent with the in vitro data, immunohistochemical detection of CD133 in 
the xeno-tumors revealed that CD133 expression was similar within the tumors formed by CD133-
positive and CD133-negative cells (Figure 27 B). The mRNA expression level of CD133 in the 
xeno-tumors formed by CD133-positive and CD133-negative cells sorted from GBM#10 and 
GBM#23 neurospheres were comparable, as shown by qRT-PCR analysis. The percentage of cells 
stained with the proliferation index Ki67 was similar in xeno-tumors formed by CD133-positive 
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Figure 27. Immunohistochemistry of xenograft tumors derived from GBM-derived neurospheres. (A) 
Representative images of brains of immunocompromised mice implanted with unsorted, CD133+ and 
CD133- cells. After sorting identical numbers of viable cells (105 cells/mouse) were implanted and brains 
examined when mice showed neurological signs. Gross images for H&E staining and coronal sections from 
representative brains bearing glioma xenografts are displayed. White line highlights tumor area. Ki67 and 
CD133 staining showed that there is no difference among tumors formed by different cell fractions.  Human 
Nuclei staining was shown in xenografts derived from GBM#23 neurospheres, since these cells formed more 
invasive tumors with no visible mass with H&E staining. Scale bar, 1000 µm (H&E and Human Nuclei) 50 
µm  (Ki67 and CD133). (B) CD133 mRNA levels are assessed by qRT-PCR in total RNA extracted from 
FFPE tissue samples (n=2 mice per group). HPRT1 (human specific) is used as reference gene for 
normalization of human CD133 expression levels. Bars show mean values and corresponding standard 





4.4. Study of the functional role of CD133 in GBM-derived neurospheres 
4.4.1 Silencing of CD133 in GBM-derived neurospheres 
A direct role of CD133 in maintaining the tumorigenic potential of glioblastoma stem/progenitor 
cells remains to be defined. To investigate the function of CD133 we silenced CD133 gene 
expression in GBM-derived neurospheres. Given the expression of CD133 in the cell cytoplasm in 
most of our neurosphere lines (only GBM#7 and GBM#24 express low levels of CD133 both on the 
plasmamembrane and in the cytoplasm), and given the capacity of the plasma membrane-associated 
CD133-negative cells to re-express CD133 at plasmamembrane level and to form tumors in xeno-
transplantation model, we targeted CD133 in all the cells that compose the neurosphere. To achieve 
a stable knock-down of CD133 in these cells, we cloned shRNAs directed against human CD133 
within a lentiviral vector, which contains GFP and Puromycin resistance gene as reporters. Two 
different shRNAs where designed to silence CD133 targeting different mRNA regions, conserved 
in all the different splice variants (see Material and Methods). 
One of them (sh2) gave a nearly complete knock-down of CD133 and was therefore used for all 
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subsequent experiments, together with the less efficient oligonucleotide sh1, as shown by Western 
blotting and qRT-PCR in figure 28. 
 
 
Figure 28. Knock-down efficiency of different shRNAs targeting CD133.  
(A) Analysis of CD133 expression by Western blotting on different GBM-derived neurospheres infected with 
lentivirus directing against either non-targeting shRNA (NT) or CD133 specific shRNAs (sh1, sh2). NI is the 
not infected control. 20 micrograms of total cell lysate were loaded on a 10% polyacrylamide gel. Actin is 
used as loading control. 
(B) The CD133 mRNA levels are assessed by qRT-PCR in cells collected 3 days after infection. TBP is used 
as reference gene for normalization of CD133 expression levels. Bars show mean values and corresponding 
standard deviation of three independent experiments. (**) p≤ 0.01 calculated with two sided Student’s t test. 
 
 
The same vector containing a shRNA targeting the luciferase mRNA sequence was used as control 
(NT, Non Targeting). Similar results were obtained in different GBM-derived neurospheres 
(GBM#9, GBM#10, GBM #18 and GBM #23). 
Immunostaining of the cells with anti-CD133 antibody, 3 days after infection and puromycin 
treatment to select infected cells, showed that the virus was indeed able to knockdown CD133 
expression in all the cells of the neurosphere, although the level of down-modulation varied among 
them (Figure 29). The silencing rate was fairly high, as only about 15% of GFP-positive cells were 






Figure 29. Knock-down efficiency of different shRNAs targeting CD133.  
(A) Representative images of GFP (green) and CD133 (red) immunofluorescence staining in GBM#9 
dissociated neurospheres infected and selected for 3 days with puromycin. DAPI (blue) is used to stain 
nuclei. Scale bar, 20 µm. (B) Percentage of GFP+ CD133- cells on the total number of nuclei is calculated. 
Bars show mean values and corresponding standard deviation of three independent fields counted. (**) p≤ 
0.01 calculated with two sided Student’s t test between groups. 
 
 
4.4.2 Silencing of CD133 reduces the proliferation of GBM-derived neurosphere cells 
When the infected cells where cultured under non-differentiating conditions and the cell viability 
was assessed by MTS/PMS assay, we found that CD133 knock-down was followed by a decrease 
in cell growth (Figure 30). The magnitude of the reduction in cell growth was proportional to the 
efficacy of the two shRNA constructs. These dose-dependent effects strongly suggest that the 
decreased growth we observed was a specific effect caused by reduction of CD133 expression. The 
reduction in cell proliferation caused by CD133 knock-down is a robust response common to 








Figure 30. CD133 silencing inhibits growth of GBM-derived neurospheres. 
Analysis of cell growth of both CD133-silenced and control cells using MTS/PMS assay. GBM-derived 
neurospheres were dissociated, infected and selected in puromycin for 3 days. Then they were plated at 3000 
cells per well in quintuplicate. SE (standard error) bars are presented at each measurement (*) p < 0.05, (**) 
p ˂ 0.01 with one-way ANOVA comparison of the control group (NT not targeting) to the corresponding 
CD133 silenced cells on the same day. 
 
 
Analysis of the proliferative index ki67 performed by immunofluorescence confirmed the reduction 
in cell proliferation, since CD133-silenced cells have significantly less ki67 stained cells, compared 
to the control (Figure 31). Any alteration in the distribution into the cell cycle phases of CD133 







Figure 31. CD133 silencing reduced the proliferation of GBM-derived neurospheres. (A) Representative 
images of immunofluorescence staining of ki67 (red) in GBM#9 dissociated neurospheres infected and 
selected for 3 days with puromycin. DAPI (blue) is used to stain nuclei. Scale bar, 50 µm. (B) Percentage of 
Ki67+ cells on the total number of nuclei is calculated. Bars show mean values and corresponding standard 
deviation of five independent fields counted. (*) p≤ 0.05and (**) p≤ 0.01 calculated with two sided Student’s 





The rate of apoptosis was studied using PI staining (Figure 32) and measure of the cleavage of 





Figure 32. Apoptosis of CD133 interfered cells.  (A) Representative plots of PI stained cells (GBM#10 NT, 
sh1, sh2). (B) Percentage of apoptotic cells in infected neurospheres derived from different patients. Bars 




No differences in the percentage of apoptotic cells between CD133 knocked-down cells and the 
control cells were detected, as confirmed by the analysis of another molecular event associated with 






Figure 33. Apoptosis of CD133 interfered cells. (A) Representative images of immunoflurescence staining 
of Cleaved caspase 3 (red) in GBM#10 dissociated neurospheres infected and selected for 3 days with 
puromycin. DAPI (blue) is used to stain nuclei. Scale bar, 50 µm. (B) Percentage of Cleaved caspasese 3+ 
cells on the total number of nuclei is calculated. Bars show mean values and corresponding standard 




These results indicate that CD133 regulates cellular proliferation and is not a survival factor for 
GBM-derived neurospheres. 
 
4.4.3 Silencing of CD133 reduces clonogenicity and self-renewal capacity of GBM-derived 
neurospheres 
Since a key characteristic of the cancer stem cells is the self-renewal capacity, we studied the 
clonogenicity of CD133 knock-down cells comparing the CD133-silenced cells to the control cells. 
Single cell suspensions were seeded on methylcellulose-coated coverslips and allowed to form 
colonies for 2 weeks. CD133 knocked-down cells formed fewer colonies than the control cells 
(Figure 34 A). Notably, CD133 knock-down decreased the clonogenic and the self-renewal 






Figure 34. Analysis of cloning efficiency of CD133 interfered cells. (A) Quantification of cloning 
efficiency of silenced cells (sh1 and sh2) compared to the control cells (NT not targeting). Bars represent 
means and corresponding standard deviation of two independent experiments. (**) p≤ 0.01 calculated with 
Student’s t test between sh1 or sh2 and NT. (B) Representative microphotographs of GBM#10 and GBM#18 




The neurospheres formed by cells with reduced CD133 expression were markedly smaller than the 
spheres formed by the control cells (Figure 34 B). When the single spheres were dissociated and 
single cells were placed in a 96-well plate, the CD133-silenced cells reformed less spheres, 







Figure 35. CD133 knock-down reduces the clonogenic capacity of GBM-derived neurosphere cells. In 
the GBM#10-derived neurospheres the number of cells within each single sphere is counted and reported as 
average number of cells (6 spheres of each group were counted). The cells are plated into 96-well plates at 
the density of 1 cell per well and the percentage of sphere formation is calculated after 2 weeks. Bars 
represent means and corresponding standard deviation of two independent experiments. (**), p ≤ 0.01 
calculated with Student’s t test between sh2 and NT. Representative microphotographs of spheres are 
presented. Scale bar, 50 µm. 
 
 
Together, these data indicate that CD133 has a function for the self-renewal potential of GBM-
neurosphere cells, although its expression is not associated with the expression of other putative 
stem cell markers. Indeed, the expression of other putative stem cell markers in glioblastoma, such 




Figure 36. CD133 knock-down does not modify the expression of other CSCs markers. (A) Analysis of 
Olig2 expression by Western blotting on different GBM-derived neurospheres infected with lentivirus 
directing against either non-targeting shRNA (NT) or CD133 specific shRNAs (sh1, sh2). 20 micrograms of 
total cell lysate were loaded on a 10% polyacrylamide gel. Actin is used as loading control. 
(B) The Olig2 mRNA levels are assessed by qRT-PCR in cells collected 3 days after infection. TBP is used 
as reference gene for normalization of Olig2 expression levels. Bars show mean values and corresponding 





4.4.4 Silencing of CD133 reduces the tumorigenic potential of the GBM neurospheres  
In order to determine the tumorigenic potential of CD133 knocked-down cells in vivo, 100000 
infected cells were injected into the brain of 5 weeks old nude mice. The animals were sacrificed at 
the first appearance of neurological signs. Almost all the mice died because of brain tumor 
formation, although a longer survival of mice injected with CD133 silenced cells occurred in all 
cases studied (injection of neurospheres derived from four different patients). Of note the fact that 
only the mice injected with cells interfered with the short hairpin 2, which was the more efficient in 









  Tumor incidence Survival Average ± SD (days) 
NT 5/5 181.2 ± 18.7 GBM#9 
sh2 5/5 171.2 ± 28.1 
NT 5/5 141.8 ± 12.9 
sh1 5/5 155.8 ± 7.1 
GBM#10 
sh2 5/5 180.5 ± 23.5 
NT 5/5 84.8 ± 7.4 
sh1 3/5 88 ± 8.1 
GBM#18 
sh2 4/5 110.5 ± 10.5 
NT 5/5 133 ± 7 GBM#23 
sh2 4/5 187 ± 6.2 
 
 
Figure 37. Kaplan-Maier survival graphs of animals injected with NT, sh1 and sh2 infected cells. 
CD133 silenced and control cells (100000 cells in each mouse) were orthotopically transplanted in nude mice 
(n = 5 animals per group). The sh2 tumor bearing mice showed a prolonged survival in GBM#10, GBM#18 
and GBM#23 cases compared to the sh1 and NT tumor bearing animals.  P-value was calculated by log rank 
test: (*) p < 0.05; (**) p < 0.01 
 
 
Almost all tumors had similar cytoarchitecture and vascularization features (Figure 38). The cells 
formed an extensive tumor that invaded the brain and completely altered its structures. 
Immunohistochemistry showed that the tumor cells expressed GFP, confirming their origin from 
infected cells. Note that, xeno-tumors derived from GBM#23 invaded dramatically the brain 
without forming a tumor visible with the hematoxilin and eosin staining. To identify human cells in 














Figure 38. Immunohistochemistry of xenograft tumors derived from infected neurospheres. 
Representative images of brains of immunocompromised mice implanted with cells isolated from the 
glioblastoma specimen GBM#9, GBM#10, GBM#18, GBM#23 and infected with non-targeting shRNA (NT) 
or CD133 shRNAs are shown. 72 hours after infection and puromycin selection identical numbers of viable 
cells (105 cells/mouse) were implanted and brains examined when mice showed neurological signs. Gross 
images for H&E staining and coronal sections from representative brains bearing glioma xenografts are 
displayed. GFP and CD133 staining showed that the tumors were formed by infected cells   Human Nuclei 
staining was shown in xenografts derived from GBM#23 infected neurospheres, since these cells formed 
more invasive tumors with no visible mass with H&E staining. Scale bar, 500µm (H&E and Human Nuclei), 
100µm (GFP), 50µm (CD133).  
 
 
Interestingly, when we looked at CD133 expression levels in these tumors we did not find any 
difference compared to the controls. This was demonstrated by immunohistochemical staining of 
CD133 on tissue slices (Figure) and by quantitative PCR on RNA extracted from formalin-fixed 




Figure 39. CD133 expression in xeno-tumors formed by infected cells. CD133 mRNA levels are assessed 
by qRT-PCR in total RNA extracted from FFPE tissue samples (n=2 mice per group). HPRT1 (human 
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specific) is used as reference gene for normalization of human CD133 expression levels. Bars show mean 
values and corresponding standard deviation of two mice. 
 
 
Moreover, neurospheres were isolated from xeno-tumors formed by CD133 silenced and control 
cells and CD133 protein expression was analyzed on total cell lysates by Western blotting.  In all 






Figure 40. Analysis of CD133 expression in neurosphere isolated from xeno-tumors. Total lysates of NT 
(not targeting), sh1 and sh2 cells were collected before injection into nude mice and in neurosphere isolated 
from xeno-tumors. Western blotting with AC133 mAb was performed with neurosphere cells derived from 
four different patients. . 10 micrograms of total cell lysate were loaded on a 10% polyacrylamide gel. 2 
micrograms total cell lysate of Caco2 are used as positive control. 10 micrograms of Hela total cell lysate are 
used as negative control. Actin is used as loading control. 
 
 
These results could be explained in different ways: either the tumors were formed by the cells 
infected with the sh2 that failed to correctly express the silencing shRNA, or the infected and 
silenced cells escaped the CD133 down-modulation, re-expressing the protein and becoming able to 
form the tumor, just like the control cells. Thus, CD133 might be important in GBM-neurospheres 





In glioblastomas, the most common primary brain tumors, CD133 identifies a subpopulation of 
stem-like tumor cells, named cancer stem cells, which drive tumor formation and are highly 
resistant to conventional chemo- and radiotherapy.  
However, several studies report the existence of glioma stem cells not expressing CD133 able to 
self-renew and retain tumorigenic potential. 
These discrepancies result in the reconsideration of CD133 as a universal marker for cancer stem 
cells in gliomas. Thus, an in-depth characterization of the complex CD133 phenotype in 
glioblastomas is much needed to re-evaluate the significance of CD133 in these tumors.  
Furthermore, questioning the utility of CD133 in the identification of CSCs implies the study of its 
possible functional role in gliomagenesis and in stem cell properties, since its function in normal 
and cancer cells is not clearly defined. 
We choose the neurosphere system as a good surrogate for in vitro study of glioma stem and 
progenitor cells (Lee et al, 2006; Rietze & Reynolds, 2006). A recent study indicates that in vitro 
expansion of GBM stem/progenitor cells as neurospheres does not alter the differentiation ability 
and the tumorigenic potential of these cells, neither their karyotype and gene expression pattern 
(Vik-Mo et al, 2010). Thus, each neurosphere cell line reflects an image of the tumor from which it 
was derived and remains representative after moderate expansion. 
The major findings of this investigation relate to the localization of CD133, reversibly modulated 
between plasmamembrane and cytoplasm by several factors not yet determinated, and to the 
functional role of CD133 in the maintenance of human GBM stem/progenitor cells. 
We found distinct expression patterns of CD133 both in neurospheres and in freshly dissociated 
tumors. Substantial amounts of membrane-bound CD133 were detectable only in a fraction of 
neurosphere lines, that we called CD133-high, whereas CD133 mRNA and intracellular CD133 
protein were found expressed at higher levels in almost all neurosphere lines examined (except 
GBM#24 and GBM#8). The existence of an intracellular pool of CD133 in addition to the one at 
the cell surface, has been demonstrated in human hematopoietic stem cells and in established 
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glioblastoma cell lines in two very recent studies (Bauer et al, 2011; Campos et al, 2011), 
confirming our results.  
Inside the cell, CD133 is located primarily in membrane vesicles within multivesicular bodies, 
endosomes, endoplasmic reticulum and Golgi apparatus (Bauer et al, 2011; Campos et al, 2011). 
Whether CD133 is localized in the same sub-cellular compartments in the neurosphere cells will be 
subject of our future investigations.  
Cell sorting, based on cell surface CD133 expression, allowed the isolation of a CD133-negative 
cell fraction composed of cells with an exclusive cytoplasmic expression of CD133. These cells 
were less clonogenic and formed tumors with a longer latency than the CD133-positive cells did. 
Notably the impairment in self-renewal capacity and tumorigenic potential of CD133-negative cells 
was lost when these cells re-expressed CD133 on the plasmamembrane. These results suggest that 
the localization of CD133 on the plasmamembrane is functionally related to the cancer stem cell 
biology and characterizes cell populations with enhanced self-renewal and tumorigenic capacity. 
These results are supported by the recent demonstrations that the cell surface location of CD133 
has been related to a higher proliferation rate of GBM cells (Wang et al, 2008). Hence, we can 
hypothesize that the cell surface CD133 activates a signaling cascade transduced into an activation 
of proliferation and self-renewal of the GBM stem/progenitor cells. 
Our experiments of blocking the cell-surface CD133 using an anti-CD133 antibody with 
consequent reduction of viability, strongly support the hypothesis of an essential role of 
plasmamembrane CD133 in the maintenance of glioma stem/progenitor cells. 
Our findings confirm the observation that cell-surface associated CD133 is a marker for self-
renewing and tumor-initiating GBM cells (Singh et al, 2004), but add the notion that the mere 
isolation of CD133-positive cells is not sufficient to enrich for a stem cell population. We indeed 
observed that also neurospheres with low cell surface CD133 expression are able to grown and 
propagate the tumor, strengthening the idea of CD133 as a non essential element for stem cell 
properties in all GBM cases. 
A recent study shows that self-renewing CD133-negative cells are present in neurosphere cultures 
derived from human GBM (Chen et al, 2010). These cells can be divided in two different types: (i) 
CD133-negative cells that generate aggressive tumors comprising a mixture of CD133-positive and 
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CD133-negative cells, (ii) CD133-negative cells that give rise to slow-growing circumscribed 
tumors formed of CD133-negative cells alone. They proposed that these cells are lineally related 
and represent different stages of differentiation. However, it was not reported any type of 
observation about a possible intracellular localization of CD133 in these two types of CD133-
negative cells. They suggested indeed a possible transcriptional regulation of CD133 rather than 
changes in sub-cellular localization. 
Through clonal analysis, we have been able to describe the intrinsic capabilities of individual tumor 
cells and their progeny. We found that every clone formed by a single CD133-negative cell contain 
cells with a considerable expression of plasmamembrane associated CD133, although in some 
cases to a lesser extent.  
Our results indicate that there is not a hierarchical relation between CD133-positive and CD133-
negative cells. Indeed, CD133 appears in an inter-convertible state, changing its expression levels 
and sub-cellular localization between the cytoplasm and the plasmamembrane. These changes 
might be regulated by several kinds of stimuli, such as the progression through the cell cycle phases 
or the supply of oxygen and nutrients. It has been demonstrated that the CD133 expression is 
strongly influenced by hypoxic conditions and is associated with alterations in mitochondrial 
function (Griguer et al, 2008).  
Additional studies are needed to determine whether the observations we are reporting occur in all 
patient tumors and may help to bridge the gap between CD133-positive and CD133-negative 
glioma stem cells. 
It remains obscure whether a population of cells that do not express CD133 at all does exist in the 
neurosphere. Interestingly, the intracellular staining of CD133 in the plasmamembrane-negative-
CD133 cell fraction reveals the existence of a cell population that does not express any CD133. It 
might be relevant the analysis of the stem cell properties of these cells, although it is impossible to 
isolate them using the FACS sorting.  
In order to identify and purify these totally CD133-negative cells, we propose to trace the activity 
of CD133 promoter in GBM-derived neurospheres. Using a lentiviral vector we could follow the 
expression of a reporter gene (e.g GFP) controlled by the human CD133 promoter. The infected 
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neurospheres could be then sorted on the basis of GFP-expression and analyzed for self-renewal 
capacity in vitro and tumorigenic potential in vivo (see APPENDIX I). 
 
5.1 Targeting CD133 expression in vivo using lentiviral mediated shRNA as new 
therapeutic approach 
The present study shows that CD133 expression is critical for several biological properties of 
human glioblastoma stem/progenitor cells. We targeted CD133 in the entire cell population of 
neurospheres derived from four different patients, using lentiviral mediated shRNA interference. 
Silencing of CD133 reduces the proliferation rate of neurosphere cells that cannot be serially 
passaged anymore.  This result is in accordance to the demonstration that CD133 expression is 
down-regulated in G0/G1 phase of the cell cycle in neural stem cells (Sun et al, 2009). Most 
importantly, depletion of CD133 reduces the self-renewal and the tumorigenic potential of GBM-
derived neurospheres, implicating that CD133 has a direct function in the initiation and progression 
of tumors. Taken together, our results indicate a functional role of CD133 in gliomagenesis, giving 
further significance to its use in the therapy of glioblastoma. 
To determine if targeting CD133 was sufficient to reduce glioma stem cell tumor growth in vivo, 
we targeted CD133 in glioma cells before injection into immunocompromised mice. 
However, to determine if targeting CD133 could represent a potential therapeutic paradigm, we 
could also target CD133 directly in established tumors. In order to test this possibility we 
intracranially implanted neurosphere cells into immunocompromised mice and allowed tumors to 
grow for 4 weeks. Tumor-bearing mice were then intracranially injected with lentivirus expressing 
non-targeting shRNA, as a control, or CD133 shRNA as a novel therapy. The shRNA targeting 
CD133 expression in vivo increased the survival of tumor-bearing animals. The tumor growth was 
not reduced by the shRNA directed against CD133, since the brain tumor xenografts were already 
well established and have formed a big and invasive tumor mass before lentivirus injection.  
Furthermore we observed expression of the reporter gene GFP in the tumor cells, confirming the 
infection with the lentivirus and we found a reduction of CD133 expression in mice receiving the 
shRNA targeting CD133 (Appendix II).  
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Although this experiment was performed only once using GBM neurospheres derived from one 
single patient, it gives us a very promising result. Much more effort will be made in the re-
production of this result and testing of CD133 in vivo targeting in several GBM-neurospheres lines.  
Taken together, our results indicate a functional role of CD133 in gliomagenesis, giving further 
significance to its use in the therapy of glioblastoma. 
It has to be taken in consideration that cytoplasmic CD133 is re-localized on the plasmamembrane, 
rendering the anti-CD133 therapy based exclusively on the targeting of cell surface-CD133, not 
effective in every case. Targeting CD133 using shRNAs might be more effective. 
 
5.2 Gene expression array suggests genes and pathways involved in the biological 
effects caused by CD133 down-regulation 
Our results suggest that CD133 influences crucial biological properties of GSCs. It is conceivable 
that CD133, directly or through its interaction with signaling pathways transducers, influences the 
maintenance and the tumorigenic potential of GSCs. 
Gene expression analysis was performed to gain insights on the identification of genes and 
pathways that might be involved in the biological effects associated with CD133 down-regulation. 
We used the Gene ST 1.0 array on RNA isolated from neurospheres derived from four different 
patients and infected with lentiviruses transducing NT and sh2 shRNAs. Slight differences in gene 
expression, common to the four samples, were found, since we observed a maximum fold change 
of 1.3 in gene expression levels between interfered and control cells. 
However, an interaction between CD133 and the Clathrin-mediated endocytosis signaling is 
strongly suggested by the finding that 6 genes belonging to this signaling pathway were found 
significantly down-regulated (p < 0.05) in all CD133 silenced neurospheres (see Appendix III A). 
The differential expression of these genes needs to be confirmed by qPCR and at protein level by 
Western blotting.  
A link between CD133 and the endocytic pathway is supported by the observation that CD133 is 
associated with the endosomal compartment of mitotic human hematopoietic stem cells (hHSCs) 
(Fonseca et al, 2008). CD133 is also associated with cholesterol-based lipid rafts whose presence in 
the endosomal compartments was recently demonstrated (Sobo et al, 2007). 
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Moreover, CD133, as well as four endosomal-associated proteins (CD53, CD62L, CD63 and 
CD71) (Beckmann et al, 2007), can be either symmetrically or asymmetrically distributed in 
mitotic hHSCs (Corbeil et al, 1998; Roper et al, 2000) 
Thus, a link between CD133, the endosomal compartment and symmetric/asymmetric cell division 
in rare primitive mammalian cells (Giebel & Beckmann, 2007) could exist. The endosomal 
compartment could host potential stem cell determinants and thus might play an active role in the 
maintenance of certain stem cell properties. Furthermore, CD133-containg lipid rafts might include 
other stem cell determinants (Fonseca et al, 2008; Kosodo et al, 2004). Thus, the concept of ‘stem 
cell-specific lipid rafts or membrane microdomains’ holding molecular determinants necessary to 
maintain the stem cell properties is attractive in this context (Marzesco et al, 2005). 
More recently, Lathia et al demonstrated that the majority of CSCs in the GBM neurospheres were 
generated through expansive symmetric cell division and not through asymmetric cell division. 
CD133, and not any other CSC marker, segregates asymmetrically in a fraction of mitoses, some of 
which were associated with Numb asymmetry. Under growth factor withdrawal conditions, the 
proportion of asymmetric CD133 distribution increases, consistently with the increase in 
asymmetric cell divisions (Lathia et al, 2011). Of note, Numb is significantly down-regulated in our 
CD133-interfered neurospheres. 
These results further suggest a link between CD133 and symmetric/asymmetric cell division of 
glioma stem cells. 
As a general consideration, our results show that CD133 alone can not be considered essential as 
cell surface marker in human glioblastomas, in agreement with the notions that cancer stem cells 
are not represented by one particular phenotype and different glioma stem cell populations (based 
on the expression of various markers) are present in this heretogeneous tumor. This conclusion is 
supported also by the fact that CD133 expression in the tumor is not related to the patients’ survival 
time; in same manner CD133 expression in the neurospheres is not related to the survival time of 
tumor bearing mice. Thus, a variety of markers has to be used to better identify stem cells in all 
tumor cases. As consequence our results do not contradict the theory of a hierarchical organization 




















CD133 mRNA expression and promoter activity based on Kemper et al.  
(A) Schematic representation of the 5′ region of CD133. Human CD133 is a highly complex gene 
that contains five alternative promoters, each containing one or multiple corresponding exons 
(Shmelkov et al, 2004). Promoter regulation exists for human CD133 and could result in seven 
different splice variants, which differ in coding exons and generate distinct protein isoforms. (B) 
Schematic representation of our working flow. To analyze promoter activity in GBM-derived 
neurospheres, promoters P1, P2, P3 active in glioma cells are amplified from genomic DNA and 
cloned into a lentiviral vector to drive the expression of the reported gene GFP. A selection gene 
(dsRED) is used to select the infected cells. The GBM-derived neurospheres are infected and 
selected on the basis of dsRED expression and the CD133 promoter activity followed by the GFP 
expression. The stem cell properties (self-renewal and tumorigenic potential) of GFP+ and GFP- 














Lentiviral shRNA targeting CD133 increased survival of mice bearing intracranial xenograft 
tumors. (A) Targeting CD133 in vivo through lentiviral mediated shRNA significantly increased 
the survival of mice bearing intracranial glioma xenografts, Seven mice per group. (**) p < 0.01. 
(B) Representative images of coronal sections of brains of mice implanted with GBM#18 
neurospheres and then infected with lentivirus expressing non-targeting shRNA (NT) or CD133 
shRNA (sh2) are shown. Identical numbers of cells (105 cells/mouse) were implanted into mice 
brains to establish intracranial tumors. After 30 days to allow the tumor to grow, lentivirus 
expressing non-targeting shRNA (NT) or shRNA directed against CD133 were delivered to the 
tumor site through direct injection. Staining of GFP indicated that the tumor cells were infected. 
(C) CD133 expression was slightly reduced in xenografts treated with shRNA directed against 
CD133. CD133 expression was analyzed by qRT-PCR in tumor xenografts. HPRT1 (human specific) 
was used as reference gene for normalization of CD133 expression levels. Bars show mean values and 
corresponding standard deviation of results derived from three mice/group. (*) p≤ 0.05 calculated with two 






















7942204 2017 CTTN 0.801 0.864 0.932 0.923 
7956088 5869 RAB5B 0.909 0.843 0.811 0.908 
7910398 5867 RAB4A 0.857 0.751 0.903 0.801 
7980005 8650 NUMB 0.8 0.903 0.909 0.891 
8052803 22848 AAK1 0.862 0.815 0.892 0.817 
8091009 5291 PIK3CB 0.857 0.835 0.843 0.779 







Microarray data. Fold change (FC) in expression for 6 genes involved in the Clathrin-mediated 
endocytic signaling differentially regulated in non-targeting shRNA (NT) cells and CD133 shRNA 







Abounader R, Laterra J (2005) Scatter factor/hepatocyte growth factor in brain tumor growth and 
angiogenesis. Neuro Oncol 7(4): 436-451 
 
Aimone JB, Wiles J, Gage FH (2006) Potential role for adult neurogenesis in the encoding of time 
in new memories. Nat Neurosci 9(6): 723-727 
 
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective 
identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100(7): 3983-3988 
 
Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover 
E, Weissleder R, Rowitch DH, Louis DN, DePinho RA (2002) Epidermal growth factor receptor 
and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along 
the neural stem cell to astrocyte axis. Cancer Cell 1(3): 269-277 
 
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN 
(2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage 
response. Nature 444(7120): 756-760 
 
Barabe F, Kennedy JA, Hope KJ, Dick JE (2007) Modeling the initiation and progression of human 
acute leukemia in mice. Science 316(5824): 600-604 
 
Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill 
DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, 
Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor 
tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma 
patients. Cancer Cell 11(1): 83-95 
 
Bauer N, Fonseca AV, Florek M, Freund D, Jaszai J, Bornhauser M, Fargeas CA, Corbeil D (2008) 
New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). 
Cells Tissues Organs 188(1-2): 127-138 
 
Bauer N, Wilsch-Brauninger M, Karbanova J, Fonseca AV, Strauss D, Freund D, Thiele C, Huttner 
WB, Bornhauser M, Corbeil D (2011) Haematopoietic stem cell differentiation promotes the 
release of prominin-1/CD133-containing membrane vesicles--a role of the endocytic-exocytic 
pathway. EMBO Mol Med 3(7): 398-409 
 
Beckmann J, Scheitza S, Wernet P, Fischer JC, Giebel B (2007) Asymmetric cell division within 
the human hematopoietic stem and progenitor cell compartment: identification of asymmetrically 
segregating proteins. Blood 109(12): 5494-5501 
 
Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, 
Bogdahn U, Beier CP (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells 
show differential growth characteristics and molecular profiles. Cancer Res 67(9): 4010-4015 
 
Beier D, Wischhusen J, Dietmaier W, Hau P, Proescholdt M, Brawanski A, Bogdahn U, Beier CP 
(2008) CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial 
tumors. Brain Pathol 18(3): 370-377 
 
Bhatia M (2001) AC133 expression in human stem cells. Leukemia 15(11): 1685-1688 
 
Bidlingmaier S, Zhu X, Liu B (2008) The utility and limitations of glycosylated human CD133 




Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC 
(2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in 
glioma tumor stem-like cells. Cell Stem Cell 4(3): 226-235 
 
Bonnefoix T, Bonnefoix P, Verdiel P, Sotto JJ (1996) Fitting limiting dilution experiments with 
generalized linear models results in a test of the single-hit Poisson assumption. J Immunol Methods 
194(2): 113-119 
 
Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that 
originates from a primitive hematopoietic cell. Nat Med 3(7): 730-737 
 
Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E (2009) 
Glioblastoma subclasses can be defined by activity among signal transduction pathways and 
associated genomic alterations. PLoS One 4(11): e7752 
 
Brescia P, Richichi C, Pelicci G (2011) Identification of glioma stem cells: what is already known 
and how far do we still need to go? The biomarkers dilemma. JCM in press 
 
Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, 
Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson 
RJ (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11(1): 69-82 
 
Cameron HA, McKay RD (2001) Adult neurogenesis produces a large pool of new granule cells in 
the dentate gyrus. J Comp Neurol 435(4): 406-417 
 
Campbell LL, Polyak K (2007) Breast tumor heterogeneity: cancer stem cells or clonal evolution? 
Cell Cycle 6(19): 2332-2338 
 
Campos B, Zeng L, Daotrong PH, Eckstein V, Unterberg A, Mairbaurl H, Herold-Mende C (2011) 
Expression and regulation of AC133 and CD133 in glioblastoma. Glia 
 
Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, 
Colman H, Lasorella A, Aldape K, Califano A, Iavarone A (2010) The transcriptional network for 
mesenchymal transformation of brain tumours. Nature 463(7279): 318-325 
 
Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magne N, Milano G (2004) 
Pharmacological background of EGFR targeting. Ann Oncol 15(7): 1007-1012 
 
Chaichana K, Zamora-Berridi G, Camara-Quintana J, Quinones-Hinojosa A (2006) Neurosphere 
assays: growth factors and hormone differences in tumor and nontumor studies. Stem Cells 24(12): 
2851-2857 
 
Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano 
RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, Lamszus K, 
Westphal M, Heim S, James CD, VandenBerg SR, Costello JF, Moorefield S, Cowdrey CJ, Prados 
M, Phillips HS (2010) A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. 
Cancer Cell 17(4): 362-375 
 
Christensen K, Schroder HD, Kristensen BW (2008) CD133 identifies perivascular niches in grade 
II-IV astrocytomas. J Neurooncol 90(2): 157-170 
 
Clarke ID, Dirks PB (2003) A human brain tumor-derived PDGFR-alpha deletion mutant is 
transforming. Oncogene 22(5): 722-733 
 
Clement V, Dutoit V, Marino D, Dietrich PY, Radovanovic I (2009) Limits of CD133 as a marker 




Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of 
tumorigenic prostate cancer stem cells. Cancer Res 65(23): 10946-10951 
 
Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, 
Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat 
K, Feuerstein BG, Jenkins RB, Aldape K (2010) A multigene predictor of outcome in glioblastoma. 
Neuro Oncol 12(1): 49-57 
 
Corbeil D, Marzesco AM, Fargeas CA, Huttner WB (2010) Prominin-1: a distinct cholesterol-
binding membrane protein and the organisation of the apical plasma membrane of epithelial cells. 
Subcell Biochem 51: 399-423 
 
Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB (2001) Prominin: a story of cholesterol, 
plasma membrane protrusions and human pathology. Traffic 2(2): 82-91 
 
Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck 
DW, Huttner WB (2000) The human AC133 hematopoietic stem cell antigen is also expressed in 
epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 275(8): 5512-5520 
 
Corbeil D, Roper K, Weigmann A, Huttner WB (1998) AC133 hematopoietic stem cell antigen: 
human homologue of mouse kidney prominin or distinct member of a novel protein family? Blood 
91(7): 2625-2626 
 
Costello JF, Plass C, Arap W, Chapman VM, Held WA, Berger MS, Su Huang HJ, Cavenee WK 
(1997) Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-
dimensional separation of genomic DNA. Cancer Res 57(7): 1250-1254 
 
Curtis MA, Kam M, Nannmark U, Anderson MF, Axell MZ, Wikkelso C, Holtas S, van Roon-
Mom WM, Bjork-Eriksson T, Nordborg C, Frisen J, Dragunow M, Faull RL, Eriksson PS (2007) 
Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. Science 
315(5816): 1243-1249 
 
Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone 
DM, Shelton AA, Parmiani G, Castelli C, Clarke MF (2007) Phenotypic characterization of human 
colorectal cancer stem cells. Proc Natl Acad Sci U S A 104(24): 10158-10163 
 
Dubreuil V, Marzesco AM, Corbeil D, Huttner WB, Wilsch-Brauninger M (2007) Midbody and 
primary cilium of neural progenitors release extracellular membrane particles enriched in the stem 
cell marker prominin-1. J Cell Biol 176(4): 483-495 
 
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, 
De Maria R (2008) Identification and expansion of the tumorigenic lung cancer stem cell 
population. Cell Death Differ 15(3): 504-514 
 
Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, 
De Maria R (2006) Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13(7): 
1238-1241 
 
Fargeas CA, Corbeil D, Huttner WB (2003) AC133 antigen, CD133, prominin-1, prominin-2, etc.: 
prominin family gene products in need of a rational nomenclature. Stem Cells 21(4): 506-508 
 
Fargeas CA, Joester A, Missol-Kolka E, Hellwig A, Huttner WB, Corbeil D (2004) Identification 
of novel Prominin-1/CD133 splice variants with alternative C-termini and their expression in 
epididymis and testis. J Cell Sci 117(Pt 18): 4301-4311 
 
Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, Scambia G (2009) 




Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB, Corbeil D (2005) 
Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human 
differentiated cells and certain types of kidney cancer. Cell Tissue Res 319(1): 15-26 
 
Fonseca AV, Bauer N, Corbeil D (2008) The stem cell marker CD133 meets the endosomal 
compartment--new insights into the cell division of hematopoietic stem cells. Blood Cells Mol Dis 
41(2): 194-195 
 
Frederick L, Eley G, Wang XY, James CD (2000) Analysis of genomic rearrangements associated 
with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro Oncol 2(3): 159-
163 
 
Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF 
(2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64(18): 6503-
6510 
 
Fuller GN, Hess KR, Rhee CH, Yung WK, Sawaya RA, Bruner JM, Zhang W (2002) Molecular 
classification of human diffuse gliomas by multidimensional scaling analysis of gene expression 
profiles parallels morphology-based classification, correlates with survival, and reveals clinically-
relevant novel glioma subsets. Brain Pathol 12(1): 108-116 
 
Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis 
DN, Brennan C, Chin L, DePinho RA, Cavenee WK (2007) Malignant astrocytic glioma: genetics, 
biology, and paths to treatment. Genes Dev 21(21): 2683-2710 
 
Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, 
Vescovi A (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from 
human glioblastoma. Cancer Res 64(19): 7011-7021 
 
Giebel B, Beckmann J (2007) Asymmetric cell divisions of human hematopoietic stem and 
progenitor cells meet endosomes. Cell Cycle 6(18): 2201-2204 
 
Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, Nozaki M, Diserens AC, 
Hamou MF, Dietrich PY, Regli L, Janzer RC, Bucher P, Stupp R, de Tribolet N, Domany E, Hegi 
ME (2003) Classification of human astrocytic gliomas on the basis of gene expression: a correlated 
group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 
63(20): 6613-6625 
 
Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, 
Yung WK (2008) VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 
10(6): 940-945 
 
Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR, Jr., Gillespie GY (2008) 
CD133 is a marker of bioenergetic stress in human glioma. PLoS One 3(11): e3655 
 
Grossman SA, Phuphanich S, Lesser G, Rozental J, Grochow LB, Fisher J, Piantadosi S (2001) 
Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. J 
Clin Oncol 19(13): 3260-3266 
 
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1): 57-70 
 
Harris MA, Yang H, Low BE, Mukherjee J, Guha A, Bronson RT, Shultz LD, Israel MA, Yun K 
(2008) Cancer stem cells are enriched in the side population cells in a mouse model of glioma. 
Cancer Res 68(24): 10051-10059 
 
Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, 
Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A (2010) Patients 
with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated 
97	  
	  
glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher 
age: implications for classification of gliomas. Acta Neuropathol 120(6): 707-718 
 
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin 
C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, 
von Deimling A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic 
and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 
118(4): 469-474 
 
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, 
Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R 
(2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 
352(10): 997-1003 
 
Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, 
Kornblum HI (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad 
Sci U S A 100(25): 15178-15183 
 
Henson JW, Schnitker BL, Correa KM, von Deimling A, Fassbender F, Xu HJ, Benedict WF, 
Yandell DW, Louis DN (1994) The retinoblastoma gene is involved in malignant progression of 
astrocytomas. Ann Neurol 36(5): 714-721 
 
Hermansen SK, Christensen KG, Jensen SS, Kristensen BW (2011) Inconsistent 
immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. 
J Histochem Cytochem 59(4): 391-407 
 
Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN (2000) Combined activation of 
Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25(1): 55-57 
 
Huse JT, Holland EC (2009) Genetically engineered mouse models of brain cancer and the promise 
of preclinical testing. Brain Pathol 19(1): 132-143 
 
Huse JT, Phillips HS, Brennan CW (2011) Molecular subclassification of diffuse gliomas: seeing 
order in the chaos. Glia 59(8): 1190-1199 
 
Huttner HB, Corbeil D, Thirmeyer C, Coras R, Kohrmann M, Mauer C, Kuramatsu JB, Kloska SP, 
Doerfler A, Weigel D, Klucken J, Winkler J, Pauli E, Schwab S, Hamer HM, Kasper BS (2005) 
Increased membrane shedding - indicated by an elevation of CD133-enriched membrane particles - 
into the CSF in partial epilepsy. Epilepsy Res 
 
Huttner HB, Janich P, Kohrmann M, Jaszai J, Siebzehnrubl F, Blumcke I, Suttorp M, Gahr M, 
Kuhnt D, Nimsky C, Krex D, Schackert G, Lowenbruck K, Reichmann H, Juttler E, Hacke W, 
Schellinger PD, Schwab S, Wilsch-Brauninger M, Marzesco AM, Corbeil D (2008) The stem cell 
marker prominin-1/CD133 on membrane particles in human cerebrospinal fluid offers novel 
approaches for studying central nervous system disease. Stem Cells 26(3): 698-705 
 
Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA (2002) Human 
cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in 
vitro. Glia 39(3): 193-206 
 
Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A (2008) Expression of the "stem 
cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 8: 48 
 
Janich P, Corbeil D (2007) GM1 and GM3 gangliosides highlight distinct lipid microdomains 




Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, Jin J, 
Hong SC, Park WY, Lee DS, Kim H, Nam DH (2008) Clinical and biological implications of 
CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 88(8): 808-815 
 
Kang MK, Kang SK (2007) Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like 
cells in brain glioma. Stem Cells Dev 16(5): 837-847 
 
Karbanova J, Missol-Kolka E, Fonseca AV, Lorra C, Janich P, Hollerova H, Jaszai J, Ehrmann J, 
Kolar Z, Liebers C, Arl S, Subrtova D, Freund D, Mokry J, Huttner WB, Corbeil D (2008) The 
stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J 
Histochem Cytochem 56(11): 977-993 
 
Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, 
Mehmet H, Stassi G, Medema JP (2010) The AC133 epitope, but not the CD133 protein, is lost 
upon cancer stem cell differentiation. Cancer Res 70(2): 719-729 
 
Kern SE, Shibata D (2007) The fuzzy math of solid tumor stem cells: a perspective. Cancer Res 
67(19): 8985-8988 
 
Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, Buchdunger E, Black PM, Stiles 
CD (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell 
growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 
60(18): 5143-5150 
 
Kosodo Y, Roper K, Haubensak W, Marzesco AM, Corbeil D, Huttner WB (2004) Asymmetric 
distribution of the apical plasma membrane during neurogenic divisions of mammalian 
neuroepithelial cells. EMBO J 23(11): 2314-2324 
 
Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters 
HV, Liau LM, Lazareff JA, Mischel PS, Cloughesy TF, Horvath S, Kornblum HI (2009) 
Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem 
Cells 27(4): 980-987 
 
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, 
Caligiuri MA, Dick JE (1994) A cell initiating human acute myeloid leukaemia after 
transplantation into SCID mice. Nature 367(6464): 645-648 
 
Lardon J, Corbeil D, Huttner WB, Ling Z, Bouwens L (2008) Stem cell marker prominin-1/AC133 
is expressed in duct cells of the adult human pancreas. Pancreas 36(1): e1-6 
 
Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, 
McLendon RE, Hjelmeland AB, Rich JN (2010) Integrin alpha 6 regulates glioblastoma stem cells. 
Cell Stem Cell 6(5): 421-432 
 
Lathia JD, Hitomi M, Gallagher J, Gadani SP, Adkins J, Vasanji A, Liu L, Eyler CE, Heddleston 
JM, Wu Q, Minhas S, Soeda A, Hoeppner DJ, Ravin R, McKay RD, McLendon RE, Corbeil D, 
Chenn A, Hjelmeland AB, Park DM, Rich JN (2011) Distribution of CD133 reveals glioma stem 
cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis 2: e200 
 
Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, 
Zhang W, Park JK, Fine HA (2006) Tumor stem cells derived from glioblastomas cultured in bFGF 
and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-
cultured cell lines. Cancer Cell 9(5): 391-403 
 
Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH, Kotliarova S, Kotliarov Y, Walling J, 
Ahn S, Kim M, Totonchy M, Cusack T, Ene C, Ma H, Su Q, Zenklusen JC, Zhang W, Maric D, 
Fine HA (2008) Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway 




Li A, Walling J, Ahn S, Kotliarov Y, Su Q, Quezado M, Oberholtzer JC, Park J, Zenklusen JC, 
Fine HA (2009) Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. 
Cancer Res 69(5): 2091-2099 
 
Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, 
Depinho RA, Anderson DJ, Stiles CD, Rowitch DH (2007) Olig2-regulated lineage-restricted 
pathway controls replication competence in neural stem cells and malignant glioma. Neuron 53(4): 
503-517 
 
Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, Foreman O, Bronson RT, 
Nishiyama A, Luo L, Zong H (2011) Mosaic analysis with double markers reveals tumor cell of 
origin in glioma. Cell 146(2): 209-221 
 
Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS (2006) 
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. 
Mol Cancer 5: 67 
 
Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, Tso JL, Liu JY, Konkankit V, 
Cloughesy TF, Mischel PS, Lane TF, Liau LM, Nelson SF, Tso CL (2009) Molecular properties of 
CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J 
Neurooncol 94(1): 1-19 
 
Lois C, Garcia-Verdugo JM, Alvarez-Buylla A (1996) Chain migration of neuronal precursors. 
Science 271(5251): 978-981 
 
Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J, Junker M, Oefner PJ, Bogdahn U, 
Wischhusen J, Spang R, Storch A, Beier CP (2010) Transcriptional profiles of CD133+ and 
CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 
70(5): 2030-2040 
 
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues 
P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 
114(2): 97-109 
 
Louis SA, Rietze RL, Deleyrolle L, Wagey RE, Thomas TE, Eaves AC, Reynolds BA (2008) 
Enumeration of neural stem and progenitor cells in the neural colony-forming cell assay. Stem Cells 
26(4): 988-996 
 
Luskin MB (1993) Restricted proliferation and migration of postnatally generated neurons derived 
from the forebrain subventricular zone. Neuron 11(1): 173-189 
 
Marzesco AM, Janich P, Wilsch-Brauninger M, Dubreuil V, Langenfeld K, Corbeil D, Huttner WB 
(2005) Release of extracellular membrane particles carrying the stem cell marker prominin-1 
(CD133) from neural progenitors and other epithelial cells. J Cell Sci 118(Pt 13): 2849-2858 
 
Marzesco AM, Wilsch-Brauninger M, Dubreuil V, Janich P, Langenfeld K, Thiele C, Huttner WB, 
Corbeil D (2009) Release of extracellular membrane vesicles from microvilli of epithelial cells is 
enhanced by depleting membrane cholesterol. FEBS Lett 583(5): 897-902 
 
Maw MA, Corbeil D, Koch J, Hellwig A, Wilson-Wheeler JC, Bridges RJ, Kumaramanickavel G, 
John S, Nancarrow D, Roper K, Weigmann A, Huttner WB, Denton MJ (2000) A frameshift 
mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum Mol Genet 9(1): 27-
34 
 
Mayer-Proschel M, Kalyani AJ, Mujtaba T, Rao MS (1997) Isolation of lineage-restricted neuronal 




Metellus P, Nanni-Metellus I, Delfino C, Colin C, Tchogandjian A, Coulibaly B, Fina F, Loundou 
A, Barrie M, Chinot O, Ouafik L, Figarella-Branger D (2011) Prognostic Impact of CD133 mRNA 
Expression in 48 Glioblastoma Patients Treated with Concomitant Radiochemotherapy: A 
Prospective Patient Cohort at a Single Institution. Ann Surg Oncol 
 
Miller CR, Perry A (2007) Glioblastoma. Arch Pathol Lab Med 131(3): 397-406 
 
Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW 
(1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, 
and molecular cloning. Blood 90(12): 5013-5021 
 
Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro 
D, Santinami M, Invernici G, Parati E, Alessandri G, La Porta CA (2007) Melanoma contains 
CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43(5): 935-
946 
 
Moore KA, Lemischka IR (2006) Stem cells and their niches. Science 311(5769): 1880-1885 
 
Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, 
Yung WK, Feuerstein BG, Aldape KD (2005) Integrated array-comparative genomic hybridization 
and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. 
Cancer Res 65(5): 1678-1686 
 
Norden AD, Drappatz J, Wen PY (2008) Novel anti-angiogenic therapies for malignant gliomas. 
Lancet Neurol 7(12): 1152-1160 
 
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, 
Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, 
Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, 
Baylin SB, Laird PW, Aldape K (2010) Identification of a CpG island methylator phenotype that 
defines a distinct subgroup of glioma. Cancer Cell 17(5): 510-522 
 
Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194(4260): 23-28 
 
Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, 
McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN 
(2003) Gene expression-based classification of malignant gliomas correlates better with survival 
than histological classification. Cancer Res 63(7): 1602-1607 
 
O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating 
tumour growth in immunodeficient mice. Nature 445(7123): 106-110 
 
Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA, Kang J, Assanah M, McKhann 
GM, Sisti MB, McCormick PC, Canoll P, Bruce JN (2008) Identification of A2B5+CD133- tumor-
initiating cells in adult human gliomas. Neurosurgery 62(2): 505-514; discussion 514-505 
 
Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J 
Pathol 170(5): 1445-1453 
 
Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, 
Maira G, Larocca LM, De Maria R (2008) Cancer stem cell analysis and clinical outcome in 
patients with glioblastoma multiforme. Clin Cancer Res 14(24): 8205-8212 
 
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, 
Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, 
Tekleab H, Diaz LA, Jr., Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, 
Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, 
101	  
	  
Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 
321(5897): 1807-1812 
 
Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung 
WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG, 2nd, 
Buckner JC, James CD, Aldape K (2007) Epidermal growth factor receptor variant III status 
defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25(16): 2288-2294 
 
Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman 
H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K (2006) Molecular subclasses 
of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble 
stages in neurogenesis. Cancer Cell 9(3): 157-173 
 
Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco 
F, Vescovi AL (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human 
brain tumour-initiating cells. Nature 444(7120): 761-765 
 
Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page 
MS, Fedoroff A, Xie D, Kelley SK (2006) Phase 1 study of erlotinib HCl alone and combined with 
temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 8(1): 67-78 
 
Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ (2008) Efficient 
tumour formation by single human melanoma cells. Nature 456(7222): 593-598 
 
Rao MS, Noble M, Mayer-Proschel M (1998) A tripotential glial precursor cell is present in the 
developing spinal cord. Proc Natl Acad Sci U S A 95(7): 3996-4001 
 
Rappa G, Fodstad O, Lorico A (2008) The stem cell-associated antigen CD133 (Prominin-1) is a 
molecular therapeutic target for metastatic melanoma. Stem Cells 26(12): 3008-3017 
 
Raso A, Mascelli S, Biassoni R, Nozza P, Kool M, Pistorio A, Ugolotti E, Milanaccio C, Pignatelli 
S, Ferraro M, Pavanello M, Ravegnani M, Cama A, Garre ML, Capra V (2011) High levels of 
PROM1 (CD133) transcript are a potential predictor of poor prognosis in medulloblastoma. Neuro 
Oncol 13(5): 500-508 
 
Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling 
R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ (2008) Phase II study 
of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for 
Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 26(28): 4659-4665 
 
Rebetz J, Tian D, Persson A, Widegren B, Salford LG, Englund E, Gisselsson D, Fan X (2008) 
Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal 
lineage differentiation potential in high-grade glioma. PLoS One 3(4): e1936 
 
Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. 
Nature 414(6859): 105-111 
 
Reynolds BA, Rietze RL (2005) Neural stem cells and neurospheres--re-evaluating the relationship. 
Nat Methods 2(5): 333-336 
 
Reynolds BA, Weiss S (1992) Generation of neurons and astrocytes from isolated cells of the adult 
mammalian central nervous system. Science 255(5052): 1707-1710 
 
Reynolds BA, Weiss S (1996) Clonal and population analyses demonstrate that an EGF-responsive 
mammalian embryonic CNS precursor is a stem cell. Dev Biol 175(1): 1-13 
 
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) 




Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi 
G, Larocca LM, De Maria R (2010) Tumour vascularization via endothelial differentiation of 
glioblastoma stem-like cells. Nature 468(7325): 824-828 
 
Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, 
Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon 
JE, 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS (2004) Phase II 
trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22(1): 133-142 
 
Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT (2004) CD133, a novel 
marker for human prostatic epithelial stem cells. J Cell Sci 117(Pt 16): 3539-3545 
 
Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor J, Hanash SM (2001) 
Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide 
microarray analysis. Cancer Res 61(18): 6885-6891 
 
Rietze RL, Reynolds BA (2006) Neural stem cell isolation and characterization. Methods Enzymol 
419: 3-23 
 
Roper K, Corbeil D, Huttner WB (2000) Retention of prominin in microvilli reveals distinct 
cholesterol-based lipid micro-domains in the apical plasma membrane. Nat Cell Biol 2(9): 582-592 
 
Sagrinati C, Netti GS, Mazzinghi B, Lazzeri E, Liotta F, Frosali F, Ronconi E, Meini C, Gacci M, 
Squecco R, Carini M, Gesualdo L, Francini F, Maggi E, Annunziato F, Lasagni L, Serio M, 
Romagnani S, Romagnani P (2006) Isolation and characterization of multipotent progenitor cells 
from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 17(9): 2443-2456 
 
Sakariassen PO, Immervoll H, Chekenya M (2007) Cancer stem cells as mediators of treatment 
resistance in brain tumors: status and controversies. Neoplasia 9(11): 882-892 
 
Salmaggi A, Boiardi A, Gelati M, Russo A, Calatozzolo C, Ciusani E, Sciacca FL, Ottolina A, 
Parati EA, La Porta C, Alessandri G, Marras C, Croci D, De Rossi M (2006) Glioblastoma-derived 
tumorospheres identify a population of tumor stem-like cells with angiogenic potential and 
enhanced multidrug resistance phenotype. Glia 54(8): 850-860 
 
Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD (2008) Tumor-specific 
immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin 
Immunol 20(5): 267-275 
 
Sanai N, Tramontin AD, Quinones-Hinojosa A, Barbaro NM, Gupta N, Kunwar S, Lawton MT, 
McDermott MW, Parsa AT, Manuel-Garcia Verdugo J, Berger MS, Alvarez-Buylla A (2004) 
Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. 
Nature 427(6976): 740-744 
 
Sasaki A, Kamiyama T, Yokoo H, Nakanishi K, Kubota K, Haga H, Matsushita M, Ozaki M, 
Matsuno Y, Todo S (2010) Cytoplasmic expression of CD133 is an important risk factor for overall 
survival in hepatocellular carcinoma. Oncol Rep 24(2): 537-546 
 
Scadden DT (2006) The stem-cell niche as an entity of action. Nature 441(7097): 1075-1079 
 
Sennino B, Falcon BL, McCauley D, Le T, McCauley T, Kurz JC, Haskell A, Epstein DM, 
McDonald DM (2007) Sequential loss of tumor vessel pericytes and endothelial cells after 
inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 67(15): 
7358-7367 
 
Shackleton M, Quintana E, Fearon ER, Morrison SJ (2009) Heterogeneity in cancer: cancer stem 




Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL (2007) 
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations 
with altered oncogenic potency. J Clin Invest 117(9): 2562-2569 
 
Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, Mischel PS, Nelson SF (2003) 
Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22(31): 4918-4923 
 
Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster 
FS, Benezra R, Kerbel RS (2006) Therapy-induced acute recruitment of circulating endothelial 
progenitor cells to tumors. Science 313(5794): 1785-1787 
 
Shirahata M, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, Takahashi JA, Kato K 
(2007) Gene expression-based molecular diagnostic system for malignant gliomas is superior to 
histological diagnosis. Clin Cancer Res 13(24): 7341-7356 
 
Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, 
White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos 
GD, D'Angelica M, Kemeny N, Lyden D, Rafii S (2008) CD133 expression is not restricted to stem 
cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 
118(6): 2111-2120 
 
Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian CA, Usenko JK, Costa C, Zhang F, Guo 
X, Rafii S (2004) Alternative promoters regulate transcription of the gene that encodes stem cell 
surface protein AC133. Blood 103(6): 2055-2061 
 
Shu Q, Wong KK, Su JM, Adesina AM, Yu LT, Tsang YT, Antalffy BC, Baxter P, Perlaky L, 
Yang J, Dauser RC, Chintagumpala M, Blaney SM, Lau CC, Li XN (2008) Direct orthotopic 
transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant 
mouse models of medulloblastoma and glioma. Stem Cells 26(6): 1414-1424 
 
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification 
of a cancer stem cell in human brain tumors. Cancer Res 63(18): 5821-5828 
 
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, 
Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432(7015): 396-401 
 
Sobo K, Le Blanc I, Luyet PP, Fivaz M, Ferguson C, Parton RG, Gruenberg J, van der Goot FG 
(2007) Late endosomal cholesterol accumulation leads to impaired intra-endosomal trafficking. 
PLoS One 2(9): e851 
 
Son MJ, Woolard K, Nam DH, Lee J, Fine HA (2009) SSEA-1 is an enrichment marker for tumor-
initiating cells in human glioblastoma. Cell Stem Cell 4(5): 440-452 
 
Soroceanu L, Kharbanda S, Chen R, Soriano RH, Aldape K, Misra A, Zha J, Forrest WF, Nigro 
JM, Modrusan Z, Feuerstein BG, Phillips HS (2007) Identification of IGF2 signaling through 
phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc 
Natl Acad Sci U S A 104(9): 3466-3471 
 
Stiles CD, Rowitch DH (2008) Glioma stem cells: a midterm exam. Neuron 58(6): 832-846 
 
Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: 
standard of care and future directions. J Clin Oncol 25(26): 4127-4136 
 
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes 
AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe 
D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and 




Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H (2006) Characterization of 
CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res 
Commun 351(4): 820-824 
 
Sun Y, Kong W, Falk A, Hu J, Zhou L, Pollard S, Smith A (2009) CD133 (Prominin) negative 
human neural stem cells are clonogenic and tripotent. PLoS One 4(5): e5498 
 
Suslov ON, Kukekov VG, Ignatova TN, Steindler DA (2002) Neural stem cell heterogeneity 
demonstrated by molecular phenotyping of clonal neurospheres. Proc Natl Acad Sci U S A 99(22): 
14506-14511 
 
Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, Magdaleno S, Dalton J, Calabrese C, 
Board J, Macdonald T, Rutka J, Guha A, Gajjar A, Curran T, Gilbertson RJ (2005) Radial glia cells 
are candidate stem cells of ependymoma. Cancer Cell 8(4): 323-335 
 
TCGA (2008) Comprehensive genomic characterization defines human glioblastoma genes and 
core pathways. Nature 455(7216): 1061-1068 
 
Thon N, Damianoff K, Hegermann J, Grau S, Krebs B, Schnell O, Tonn JC, Goldbrunner R (2010) 
Presence of pluripotent CD133+ cells correlates with malignancy of gliomas. Mol Cell Neurosci 
43(1): 51-59 
 
Toma JG, Akhavan M, Fernandes KJ, Barnabe-Heider F, Sadikot A, Kaplan DR, Miller FD (2001) 
Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol 3(9): 
778-784 
 
Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, 
Weissman IL (2000) Direct isolation of human central nervous system stem cells. Proc Natl Acad 
Sci U S A 97(26): 14720-14725 
 
Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC (2002) Ink4a-Arf loss 
cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of 
various morphologies depending on activated Akt. Cancer Res 62(19): 5551-5558 
 
van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS, Sommer C, 
Reifenberger G, Hanash SM (2003) Characterization of gene expression profiles associated with 
glioma progression using oligonucleotide-based microarray analysis and real-time reverse 
transcription-polymerase chain reaction. Am J Pathol 163(3): 1033-1043 
 
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub 
T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, 
Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, 
Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN (2010) 
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by 
abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1): 98-110 
 
Vescovi AL, Galli R, Reynolds BA (2006) Brain tumour stem cells. Nat Rev Cancer 6(6): 425-436 
 
Vik-Mo EO, Sandberg C, Olstorn H, Varghese M, Brandal P, Ramm-Pettersen J, Murrell W, 
Langmoen IA (2010) Brain tumor stem cells maintain overall phenotype and tumorigenicity after in 
vitro culturing in serum-free conditions. Neuro Oncol 
 
Vital AL, Tabernero MD, Castrillo A, Rebelo O, Tao H, Gomes F, Nieto AB, Resende Oliveira C, 
Lopes MC, Orfao A (2010) Gene expression profiles of human glioblastomas are associated with 




von Deimling A, Korshunov A, Hartmann C (2011) The next generation of glioma biomarkers: 
MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21(1): 74-87 
 
Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, 
Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, 
Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin 
Oncol 25(30): 4722-4729 
 
Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, Prestegarden L, 
Rosland G, Thorsen F, Stuhr L, Molven A, Bjerkvig R, Enger PO (2008) CD133 negative glioma 
cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 122(4): 761-768 
 
Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, 
Brennan C, Tabar V (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 
468(7325): 829-833 
 
Weigmann A, Corbeil D, Hellwig A, Huttner WB (1997) Prominin, a novel microvilli-specific 
polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal 
protrusions of non-epithelial cells. Proc Natl Acad Sci U S A 94(23): 12425-12430 
 
Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5): 492-507 
 
Westermark B, Heldin CH, Nister M (1995) Platelet-derived growth factor in human glioma. Glia 
15(3): 257-263 
 
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, 
Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, 
Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8): 765-
773 
 
Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, 
Buck DW (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. 
Blood 90(12): 5002-5012 
 
Yu JW, Zhang P, Wu JG, Wu SH, Li XQ, Wang ST, Lu RQ, Ni XC, Jiang BJ (2010) Expressions 
and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric 
adenocacinoma. J Exp Clin Cancer Res 29: 141 
 
Yuan H, Corbi N, Basilico C, Dailey L (1995) Developmental-specific activity of the FGF-4 
enhancer requires the synergistic action of Sox2 and Oct-3. Genes Dev 9(21): 2635-2645 
 
Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL, Yu JS (2004) 
Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23(58): 9392-9400 
 
Zacchigna S, Oh H, Wilsch-Brauninger M, Missol-Kolka E, Jaszai J, Jansen S, Tanimoto N, 
Tonagel F, Seeliger M, Huttner WB, Corbeil D, Dewerchin M, Vinckier S, Moons L, Carmeliet P 
(2009) Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis 
and photoreceptor degeneration. J Neurosci 29(7): 2297-2308 
 
Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, 
Radlwimmer B, Herold-Mende CC (2008) Stem cell marker CD133 affects clinical outcome in 
glioma patients. Clin Cancer Res 14(1): 123-129 
 
Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, Fang J (2008) Nestin and CD133: valuable 
stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer 




Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, 
Ellison DW, Gilbertson RJ (2009) Prominin 1 marks intestinal stem cells that are susceptible to 
neoplastic transformation. Nature 457(7229): 603-607 
 
 
 
